Cluster composition

Functions

Category	Name	IntersectionWithQuery	PValue	GenesInTerm	GenesInQuery	GenesInTermInQuery	ID
GeneOntologyMolecularFunction	calcium ion binding	SYT12 SYT3 PCLO PLCD4 BCAN ADGRV1 RET HRNR CPS1 RYR2 PCDHB18P MYOF FAT1 FAT2 EFHC1 MAN1A2 EGFLAM CDH2 ATP2B2 PCDH7 CDH10 NOTCH3	6.36e-07	749	174	22	GO:0005509
GeneOntologyMolecularFunction	enzyme regulator activity	RGPD4 PPP4R1 RANBP2 RAP1GDS1 RGPD8 DOCK11 DOCK9 SERPINF1 IQSEC2 PLCD4 ADGRV1 GDI2 RGS3 AREG FETUB MMP25 MALT1 IBTK KIDINS220 RALGPS1 PPP4R2 AKAP11 NKX3-1 BSN RASAL2 RGPD5 SOS2	9.95e-05	1418	174	27	GO:0030234
GeneOntologyMolecularFunction	nucleoside-triphosphatase regulator activity	RGPD4 RANBP2 RAP1GDS1 RGPD8 DOCK11 DOCK9 IQSEC2 PLCD4 GDI2 RGS3 RALGPS1 RASAL2 RGPD5 SOS2	1.48e-04	507	174	14	GO:0060589
GeneOntologyMolecularFunction	GTPase regulator activity	RGPD4 RANBP2 RAP1GDS1 RGPD8 DOCK11 DOCK9 IQSEC2 PLCD4 GDI2 RGS3 RALGPS1 RASAL2 RGPD5 SOS2	1.48e-04	507	174	14	GO:0030695
GeneOntologyMolecularFunction	A-type (transient outward) potassium channel activity	KCND1 KCND2	4.48e-04	4	174	2	GO:0005250
GeneOntologyMolecularFunction	small GTPase binding	RGPD4 MAPKAP1 RANBP2 RGPD8 DOCK11 DOCK9 GDI2 HACE1 IPO13 GARRE1	5.29e-04	321	174	10	GO:0031267
GeneOntologyBiologicalProcess	NLS-bearing protein import into nucleus	RGPD4 RANBP2 RGPD8 RGPD5	2.04e-05	20	172	4	GO:0006607
GeneOntologyBiologicalProcess	homophilic cell adhesion via plasma membrane adhesion molecules	CHL1 ESAM RET PCDHB18P FAT1 FAT2 CDH2 PCDH7 CDH10	2.82e-05	187	172	9	GO:0007156
GeneOntologyBiologicalProcess	positive regulation of glucokinase activity	RGPD4 RANBP2 RGPD8	4.61e-05	9	172	3	GO:0033133
GeneOntologyBiologicalProcess	small GTPase-mediated signal transduction	CUL3 MAPKAP1 KRAS DOCK11 DOCK9 IQSEC2 PLCD4 RRAD GDI2 NFIX RALGPS1 HACE1 CDH2 GARRE1 SOS2	4.71e-05	538	172	15	GO:0007264
GeneOntologyBiologicalProcess	positive regulation of hexokinase activity	RGPD4 RANBP2 RGPD8	6.55e-05	10	172	3	GO:1903301
GeneOntologyCellularComponent	ribbon synapse	PCLO IQSEC2 EGFLAM BSN ATP2B2	6.16e-06	32	173	5	GO:0097470
GeneOntologyCellularComponent	cytoplasmic periphery of the nuclear pore complex	RGPD4 RANBP2 RGPD8	3.03e-05	8	173	3	GO:1990723
GeneOntologyCellularComponent	nuclear pore cytoplasmic filaments	RGPD4 RANBP2 RGPD8	6.41e-05	10	173	3	GO:0044614
GeneOntologyCellularComponent	ATPase complex	ACTR8 BICRA GON4L BPTF ATP6V0A4 YY1AP1 ATP6V0D2	1.01e-04	129	173	7	GO:1904949
GeneOntologyCellularComponent	presynaptic active zone	PCLO IQSEC2 EGFLAM BSN CDH2 ATP2B2 CDH10	1.76e-04	141	173	7	GO:0048786
GeneOntologyCellularComponent	annulate lamellae	RGPD4 RANBP2 RGPD8	1.90e-04	14	173	3	GO:0005642
GeneOntologyCellularComponent	Ino80 complex	ACTR8 GON4L YY1AP1	3.48e-04	17	173	3	GO:0031011
GeneOntologyCellularComponent	multi-eIF complex	EIF1AY EIF1AX	4.04e-04	4	173	2	GO:0043614
GeneOntologyCellularComponent	USH2 complex	PDZD7 ADGRV1	4.04e-04	4	173	2	GO:1990696
GeneOntologyCellularComponent	photoreceptor ribbon synapse	IQSEC2 EGFLAM ATP2B2	4.15e-04	18	173	3	GO:0098684
GeneOntologyCellularComponent	nuclear pore nuclear basket	RGPD4 RANBP2 RGPD8	4.15e-04	18	173	3	GO:0044615
GeneOntologyCellularComponent	nuclear inclusion body	RGPD4 RANBP2 RGPD8	5.73e-04	20	173	3	GO:0042405
GeneOntologyCellularComponent	SUMO ligase complex	RGPD4 RANBP2 RGPD8	6.64e-04	21	173	3	GO:0106068
GeneOntologyCellularComponent	CBM complex	MALT1 CARD9	6.70e-04	5	173	2	GO:0032449
GeneOntologyCellularComponent	presynaptic active zone cytoplasmic component	PCLO IQSEC2 BSN	8.73e-04	23	173	3	GO:0098831
GeneOntologyCellularComponent	stereocilia ankle link	PDZD7 ADGRV1	9.99e-04	6	173	2	GO:0002141
GeneOntologyCellularComponent	stereocilia ankle link complex	PDZD7 ADGRV1	9.99e-04	6	173	2	GO:0002142
GeneOntologyCellularComponent	protein phosphatase 4 complex	PPP4R1 PPP4R2	9.99e-04	6	173	2	GO:0030289
GeneOntologyCellularComponent	SWI/SNF superfamily-type complex	ACTR8 BICRA GON4L BPTF YY1AP1	1.22e-03	96	173	5	GO:0070603
GeneOntologyCellularComponent	INO80-type complex	ACTR8 GON4L YY1AP1	1.57e-03	28	173	3	GO:0097346
GeneOntologyCellularComponent	stereocilia coupling link	PDZD7 ADGRV1	1.85e-03	8	173	2	GO:0002139
GeneOntologyCellularComponent	cytoskeleton of presynaptic active zone	PCLO BSN	1.85e-03	8	173	2	GO:0048788
GeneOntologyCellularComponent	GABA-ergic synapse	PCLO BCAN KCND2 BSN ATP2B2 CDH10	2.47e-03	164	173	6	GO:0098982
MousePheno	increased organ/body region tumor incidence	RGPD4 KRAS SMG1 RANBP2 RGPD8 ATAD5 ACOX1 PEX1 MUS81 GON4L RET BRCA1 HACE1 YY1AP1 NKX3-1 CDK11B	3.39e-06	395	145	16	MP:0010274
MousePheno	abnormal organ/body region tumor incidence	RGPD4 KRAS SMG1 RANBP2 RGPD8 ATAD5 ACOX1 PEX1 MUS81 GON4L RET BRCA1 HACE1 YY1AP1 NKX3-1 CDK11B	4.11e-06	401	145	16	MP:0013152
MousePheno	increased carcinoma incidence	RGPD4 KRAS SMG1 RANBP2 RGPD8 ATAD5 ACOX1 MUS81 GON4L BRCA1 YY1AP1	6.44e-06	197	145	11	MP:0002038
MousePheno	increased classified tumor incidence	RGPD4 KRAS SMG1 RANBP2 RGPD8 ATAD5 ACOX1 PEX1 MUS81 GON4L RET BRCA1 HACE1 YY1AP1 CDK11B	9.81e-06	381	145	15	MP:0010273
MousePheno	abnormal classified tumor incidence	RGPD4 KRAS SMG1 RANBP2 RGPD8 ATAD5 ACOX1 PEX1 MUS81 GON4L RET BRCA1 HACE1 YY1AP1 CDK11B	1.08e-05	384	145	15	MP:0020188
MousePheno	decreased tumor latency	RGPD4 RANBP2 RGPD8 ALDH2 RASAL2	1.30e-05	30	145	5	MP:0010308
MousePheno	abnormal prostate gland epithelium morphology	SERPINF1 RLN1 RLN2 NKX3-1	1.83e-05	16	145	4	MP:0001168
MousePheno	abnormal tumor latency	RGPD4 RANBP2 RGPD8 ALDH2 RASAL2	2.45e-05	34	145	5	MP:0010307
MousePheno	abnormal rod electrophysiology	RGPD4 RPGRIP1 RANBP2 RGPD8 NAGLU PEX1 CCDC66 EGFLAM	3.28e-05	119	145	8	MP:0004021
MousePheno	increased tumor incidence	RGPD4 KRAS SMG1 RANBP2 RGPD8 ATAD5 ACOX1 PEX1 MUS81 GON4L RET BRCA1 HACE1 YY1AP1 NKX3-1 CDK11B ALDH2	3.50e-05	530	145	17	MP:0002020
MousePheno	increased malignant tumor incidence	RGPD4 KRAS SMG1 RANBP2 RGPD8 ATAD5 ACOX1 MUS81 GON4L BRCA1 YY1AP1	3.63e-05	237	145	11	MP:0002018
MousePheno	abnormal tumor susceptibility	RGPD4 KRAS SMG1 RANBP2 RGPD8 ATAD5 ACOX1 PEX1 MUS81 GON4L ESAM RET BRCA1 HACE1 YY1AP1 NKX3-1 CDK11B ALDH2 RASAL2	4.22e-05	650	145	19	MP:0002166
MousePheno	neoplasm	RGPD4 KRAS SMG1 RANBP2 RGPD8 ATAD5 ACOX1 PEX1 MUS81 GON4L ESAM RET BRCA1 HACE1 YY1AP1 NKX3-1 CDK11B ALDH2 DOT1L RASAL2	8.87e-05	747	145	20	MP:0002006
MousePheno	increased gland tumor incidence	KRAS ATAD5 GON4L RET BRCA1 HACE1 YY1AP1 NKX3-1	9.90e-05	139	145	8	MP:0010288
MousePheno	abnormal tumor incidence	RGPD4 KRAS SMG1 RANBP2 RGPD8 ATAD5 ACOX1 PEX1 MUS81 GON4L ESAM RET BRCA1 HACE1 YY1AP1 NKX3-1 CDK11B ALDH2	1.01e-04	635	145	18	MP:0002019
MousePheno	increased salivary adenocarcinoma incidence	GON4L YY1AP1	1.07e-04	2	145	2	MP:0000621
MousePheno	increased respiratory system tumor incidence	RGPD4 KRAS SMG1 RANBP2 RGPD8 ATAD5 HACE1	1.23e-04	107	145	7	MP:0010298
MousePheno	increased lung tumor incidence	RGPD4 KRAS SMG1 RANBP2 RGPD8 ATAD5 HACE1	1.23e-04	107	145	7	MP:0008014
MousePheno	abnormal eye electrophysiology	RGPD4 RPGRIP1 RANBP2 RGPD8 LAMA1 NAGLU PEX1 ADGRV1 CCDC66 EGFLAM	1.32e-04	228	145	10	MP:0005551
MousePheno	increased hepatobiliary system tumor incidence	RGPD4 RANBP2 RGPD8 ATAD5 ACOX1 PEX1 BRCA1	1.54e-04	111	145	7	MP:0010297
MousePheno	increased liver tumor incidence	RGPD4 RANBP2 RGPD8 ATAD5 ACOX1 PEX1 BRCA1	1.54e-04	111	145	7	MP:0008019
MousePheno	increased lung carcinoma incidence	RGPD4 KRAS SMG1 RANBP2 RGPD8 ATAD5	1.56e-04	78	145	6	MP:0008714
MousePheno	abnormal prostate gland development	RLN1 RLN2 NKX3-1	1.70e-04	11	145	3	MP:0009735
MousePheno	abnormal temporal lobe morphology	CHL1 CUL3 IQSEC2 BCAN SHANK3 EFHC1 NFIX BTG1 ALDH2 CDH2 ATP2B2 PLXNA2	2.03e-04	337	145	12	MP:0000801
MousePheno	abnormal chromosome number	RGPD4 RANBP2 RGPD8 ATAD5 BRCA1 DOT1L	2.67e-04	86	145	6	MP:0004023
MousePheno	increased apoptosis	ALX3 CUL3 MAPKAP1 KRAS SMG1 RAP1GDS1 AMER1 KCTD19 LAMA1 GJC1 RET GDI2 RLN1 TFRC RLN2 KIDINS220 BRCA1 BTG1 PLCG2 CDK11B ALDH2 DOT1L WDR62	2.76e-04	1008	145	23	MP:0006042
MousePheno	increased cell death	ALX3 CUL3 MAPKAP1 KRAS SMG1 RAP1GDS1 AMER1 KCTD19 LAMA1 GJC1 RET GDI2 RLN1 TFRC RLN2 KIDINS220 BRCA1 BTG1 PLCG2 CDK11B ALDH2 DOT1L WDR62	3.23e-04	1019	145	23	MP:0012556
MousePheno	premature neuronal precursor differentiation	PTBP2 METTL14 WDR62	3.66e-04	14	145	3	MP:0003424
MousePheno	abnormal hair cell mechanoelectric transduction	PDZD7 ADGRV1 ATP2B2	3.66e-04	14	145	3	MP:0004431
MousePheno	absent B cells	GON4L DCLRE1C YY1AP1	3.66e-04	14	145	3	MP:0008071
MousePheno	aneuploidy	RGPD4 RANBP2 RGPD8 ATAD5 DOT1L	4.18e-04	61	145	5	MP:0004024
MousePheno	increased blood osmolality	RLN1 RLN2 ATP6V0A4	5.54e-04	16	145	3	MP:0008997
MousePheno	elevated level of mitotic sister chromatid exchange	RGPD4 RANBP2 RGPD8	5.54e-04	16	145	3	MP:0003701
MousePheno	abnormal limbic system morphology	CHL1 CUL3 IQSEC2 NAGLU BCAN SHANK3 EFHC1 NFIX BTG1 ALDH2 CDH2 PLXNA2	5.73e-04	378	145	12	MP:0004166
MousePheno	decreased nipple size	RLN1 RLN2	6.32e-04	4	145	2	MP:0013713
MousePheno	decreased paired-pulse ratio	SHANK3 RYR2	6.32e-04	4	145	2	MP:0014253
MousePheno	abnormal blood osmolality	RLN1 RLN2 ATP6V0A4	6.68e-04	17	145	3	MP:0008996
MousePheno	abnormal hippocampus morphology	CHL1 CUL3 IQSEC2 BCAN SHANK3 EFHC1 NFIX BTG1 ALDH2 CDH2 PLXNA2	6.69e-04	331	145	11	MP:0000807
Domain	Ran_BP1	RGPD4 RANBP2 RGPD8 RGPD5	3.25e-06	12	172	4	PF00638
Domain	RANBD1	RGPD4 RANBP2 RGPD8 RGPD5	3.25e-06	12	172	4	PS50196
Domain	C2	RPGRIP1 SYT12 SYT3 PCLO PLCD4 RGS3 MYOF PLCG2 RASAL2	3.49e-06	131	172	9	PF00168
Domain	RanBD	RGPD4 RANBP2 RGPD8 RGPD5	4.65e-06	13	172	4	SM00160
Domain	Ran_bind_dom	RGPD4 RANBP2 RGPD8 RGPD5	4.65e-06	13	172	4	IPR000156
Domain	C2	RPGRIP1 SYT12 SYT3 PCLO PLCD4 RGS3 MYOF PLCG2 RASAL2	5.05e-06	137	172	9	SM00239
Domain	C2	RPGRIP1 SYT12 SYT3 PCLO PLCD4 RGS3 MYOF PLCG2 RASAL2	6.76e-06	142	172	9	PS50004
Domain	-	RPGRIP1 SYT12 SYT3 PCLO PLCD4 RGS3 MYOF PLCG2 RASAL2	9.47e-06	148	172	9	2.60.40.150
Domain	PH_dom-like	RGPD4 RANBP2 RGPD8 DOCK11 DOCK9 IQSEC2 FERMT1 PLCD4 RGS3 RALGPS1 TLN1 PLCG2 RASAL2 RGPD5 SOS2	9.81e-06	426	172	15	IPR011993
Domain	-	RGPD4 RANBP2 RGPD8 DOCK11 DOCK9 IQSEC2 FERMT1 PLCD4 RGS3 RALGPS1 TLN1 PLCG2 RASAL2 SOS2	1.63e-05	391	172	14	2.30.29.30
Domain	C2_dom	RPGRIP1 SYT12 SYT3 PCLO PLCD4 RGS3 MYOF PLCG2 RASAL2	2.16e-05	164	172	9	IPR000008
Domain	TIF_eIF-1A_CS	EIF1AY EIF1AX	8.43e-05	2	172	2	IPR018104
Domain	Znf_piccolo	PCLO BSN	8.43e-05	2	172	2	IPR008899
Domain	zf-piccolo	PCLO BSN	8.43e-05	2	172	2	PF05715
Domain	DUF4939	RTL8B RTL8A RTL8C	8.78e-05	10	172	3	IPR032549
Domain	DUF4939	RTL8B RTL8A RTL8C	8.78e-05	10	172	3	PF16297
Domain	Grip	RGPD4 RGPD8 RGPD5	1.20e-04	11	172	3	SM00755
Domain	LDOC1-rel	RTL8B RTL8A RTL8C	1.20e-04	11	172	3	IPR032567
Domain	GRIP	RGPD4 RGPD8 RGPD5	1.20e-04	11	172	3	PF01465
Domain	GRIP_dom	RGPD4 RGPD8 RGPD5	1.59e-04	12	172	3	IPR000237
Domain	GRIP	RGPD4 RGPD8 RGPD5	1.59e-04	12	172	3	PS50913
Domain	Laminin_G	LAMA1 FAT1 FAT2 COL21A1 EGFLAM	1.93e-04	58	172	5	IPR001791
Domain	-	LAMA1 ADGRV1 FAT1 FAT2 COL21A1 EGFLAM	2.47e-04	95	172	6	2.60.120.200
Domain	Shal-type_N	KCND1 KCND2	2.51e-04	3	172	2	IPR021645
Domain	TIF_eIF-1A	EIF1AY EIF1AX	2.51e-04	3	172	2	PD005579
Domain	K_chnl_volt-dep_Kv4_C	KCND1 KCND2	2.51e-04	3	172	2	IPR024587
Domain	DUF3399	KCND1 KCND2	2.51e-04	3	172	2	PF11879
Domain	K_chnl_volt-dep_Kv4	KCND1 KCND2	2.51e-04	3	172	2	IPR003975
Domain	Shal-type	KCND1 KCND2	2.51e-04	3	172	2	PF11601
Domain	Relaxin	RLN1 RLN2	2.51e-04	3	172	2	IPR022421
Domain	IF1A	EIF1AY EIF1AX	2.51e-04	3	172	2	PS01262
Domain	LAM_G_DOMAIN	LAMA1 FAT1 FAT2 EGFLAM	4.02e-04	38	172	4	PS50025
Domain	Laminin_G_2	LAMA1 FAT1 FAT2 EGFLAM	4.90e-04	40	172	4	PF02210
Domain	S1_IF1_TYPE	EIF1AY EIF1AX	5.00e-04	4	172	2	PS50832
Domain	FERM_f0	SHANK3 TLN1	5.00e-04	4	172	2	PF16511
Domain	TIF_eIF-1A	EIF1AY EIF1AX	5.00e-04	4	172	2	IPR001253
Domain	eIF1a	EIF1AY EIF1AX	5.00e-04	4	172	2	SM00652
Domain	RNA-binding_domain_S1_IF1	EIF1AY EIF1AX	5.00e-04	4	172	2	IPR006196
Domain	FERM_f0	SHANK3 TLN1	5.00e-04	4	172	2	IPR032425
Domain	eIF-1a	EIF1AY EIF1AX	5.00e-04	4	172	2	PF01176
Domain	Cadherin	RET FAT1 FAT2 CDH2 PCDH7 CDH10	6.26e-04	113	172	6	PF00028
Domain	CADHERIN_2	RET FAT1 FAT2 CDH2 PCDH7 CDH10	6.56e-04	114	172	6	PS50268
Domain	-	RET FAT1 FAT2 CDH2 PCDH7 CDH10	6.56e-04	114	172	6	2.60.40.60
Domain	CA	RET FAT1 FAT2 CDH2 PCDH7 CDH10	6.87e-04	115	172	6	SM00112
Domain	LamG	LAMA1 FAT1 FAT2 EGFLAM	7.07e-04	44	172	4	SM00282
Domain	Cadherin-like	RET FAT1 FAT2 CDH2 PCDH7 CDH10	7.19e-04	116	172	6	IPR015919
Domain	Synaptotagmin	SYT12 SYT3 PCLO	7.80e-04	20	172	3	IPR001565
Domain	Cadherin	RET FAT1 FAT2 CDH2 PCDH7 CDH10	7.87e-04	118	172	6	IPR002126
Domain	EGF	BCAN AREG FAT1 FAT2 EGFLAM NOTCH3	1.11e-03	126	172	6	PF00008
Domain	PH	DOCK11 DOCK9 IQSEC2 FERMT1 PLCD4 RALGPS1 PLCG2 RASAL2 SOS2	1.12e-03	278	172	9	SM00233
Domain	PH_DOMAIN	DOCK11 DOCK9 IQSEC2 FERMT1 PLCD4 RALGPS1 PLCG2 RASAL2 SOS2	1.15e-03	279	172	9	PS50003
Domain	PH_domain	DOCK11 DOCK9 IQSEC2 FERMT1 PLCD4 RALGPS1 PLCG2 RASAL2 SOS2	1.18e-03	280	172	9	IPR001849
Domain	Insulin_family	RLN1 RLN2	1.23e-03	6	172	2	IPR022352
Domain	DUF3398	DOCK11 DOCK9	1.23e-03	6	172	2	PF11878
Domain	DOCK_C/D_N	DOCK11 DOCK9	1.23e-03	6	172	2	IPR021816
Domain	Rab_bind	RGPD4 RGPD8	1.72e-03	7	172	2	PF16704
Domain	GCC2_Rab_bind	RGPD4 RGPD8	1.72e-03	7	172	2	IPR032023
Pubmed	A low-copy repeat in Xq26 represents a novel putatively prenylated protein gene (CXX1) and its pseudogenes (DXS9914, DXS9915, and DXS9916).	RTL8B RTL8A RTL8C	1.32e-07	3	178	3	9403077
Pubmed	Identification of a novel Ran binding protein 2 related gene (RANBP2L1) and detection of a gene cluster on human chromosome 2q11-q12.	RANBP2 RGPD8 RGPD5	5.25e-07	4	178	3	9480752
Pubmed	Spatiotemporal profile of postsynaptic interactomes integrates components of complex brain disorders.	RGPD4 CUL3 KRAS RANBP2 RGPD8 SYT3 DOCK11 FXR2 IQSEC2 GDI2 SHANK3 ADD1 IGF2R PLPPR4 SVIL BSN CDH2 CDH10 RASAL2	5.90e-07	963	178	19	28671696
Pubmed	Prediction of the coding sequences of mouse homologues of KIAA gene: III. the complete nucleotide sequences of 500 mouse KIAA-homologous cDNAs identified by screening of terminal sequences of cDNA clones randomly sampled from size-fractionated libraries.	CUL3 SMG1 WAPL ADGRV1 METTL14 EFR3A IBTK PLPPR4 RALGPS1 IPO13 SENP6 AKAP11 BSN GARRE1	6.69e-07	529	178	14	14621295
Pubmed	Limited expression of nuclear pore membrane glycoprotein 210 in cell lines and tissues suggests cell-type specific nuclear pores in metazoans.	RGPD4 RANBP2 RGPD8 LAMA1	8.66e-07	15	178	4	14697343
Pubmed	Protein interactome reveals converging molecular pathways among autism disorders.	RGPD8 FXR2 CYP51A1 BSDC1 MCM6 TACC2 WDR59 SHANK3 TASOR2 UBP1 FBXO7 IPO13 YY1AP1 NOTCH3	1.31e-06	560	178	14	21653829
Pubmed	Voltage-dependent conformational changes of Kv1.3 channels activate cell proliferation.	CHL1 EPPK1 RPN1 LAMA1 RNF213 KIDINS220 TLN1 SENP6 BSN	1.39e-06	208	178	9	33230847
Pubmed	In-Depth In Vivo Crosslinking in Minutes by a Compact, Membrane-Permeable, and Alkynyl-Enrichable Crosslinker.	RGPD4 RPGRIP1 SMG1 FAM184B RANBP2 AMER1 RGPD8 RPN1 PTBP2 PCLO TAF1B RYR2 TASOR2 TFRC PDIA4 BPTF BRCA1 GTF2IRD2 ALDH2 BSN ATP2B2 PLXNA2 RGPD5	1.44e-06	1442	178	23	35575683
Pubmed	The Functional Proximal Proteome of Oncogenic Ras Includes mTORC2.	MAPKAP1 KRAS DOCK9 FERMT1 GJC1 TFRC EFR3A FAT1 IGF2R KIDINS220 TANC1 PCDH7 PLXNA2 RASAL2	1.57e-06	569	178	14	30639242
Pubmed	Interaction network of human early embryonic transcription factors.	RANBP2 RPN1 BICRA NAB1 HRNR TFRC PDIA4 BPTF CDH2 CPVL MED12	2.20e-06	351	178	11	38297188
Pubmed	Structural basis for the nuclear export activity of Importin13.	EIF1AY EIF1AX IPO13	2.61e-06	6	178	3	23435562
Pubmed	RTL8 promotes nuclear localization of UBQLN2 to subnuclear compartments associated with protein quality control.	RTL8B RTL8A RTL8C	2.61e-06	6	178	3	35247097
Pubmed	ESCPE-1 mediates retrograde endosomal sorting of the SARS-CoV-2 host factor Neuropilin-1.	SYT12 RPN1 CYP51A1 LAMA1 NAGLU RNF213 TFRC PDIA4 IGSF10 MYOF FAT1 MAN1A2 IGF2R SVIL IPO13 CDH2 CPVL PCDH7 NOTCH3 WDR62	3.91e-06	1201	178	20	35696571
Pubmed	TIF1γ inhibits lung adenocarcinoma EMT and metastasis by interacting with the TAF15/TBP complex.	RANBP2 RPN1 GART MCM6 CPS1 TFRC PDIA4 BPTF	4.26e-06	179	178	8	36261009
Pubmed	Interconversion of red opsin isoforms by the cyclophilin-related chaperone protein Ran-binding protein 2.	RGPD4 RANBP2 RGPD8	4.54e-06	7	178	3	9037092
Pubmed	Nup358, a nucleoporin, functions as a key determinant of the nuclear pore complex structure remodeling during skeletal myogenesis.	RGPD4 RANBP2 RGPD8	4.54e-06	7	178	3	21205196
Pubmed	Differential loss of prolyl isomerase or chaperone activity of Ran-binding protein 2 (Ranbp2) unveils distinct physiological roles of its cyclophilin domain in proteostasis.	RGPD4 RANBP2 RGPD8	4.54e-06	7	178	3	24403063
Pubmed	Kinesin-1 and mitochondrial motility control by discrimination of structurally equivalent but distinct subdomains in Ran-GTP-binding domains of Ran-binding protein 2.	RGPD4 RANBP2 RGPD8	4.54e-06	7	178	3	23536549
Pubmed	Identification of RanBP2- and kinesin-mediated transport pathways with restricted neuronal and subcellular localization.	RGPD4 RANBP2 RGPD8	4.54e-06	7	178	3	12191015
Pubmed	Ranbp2 haploinsufficiency mediates distinct cellular and biochemical phenotypes in brain and retinal dopaminergic and glia cells elicited by the Parkinsonian neurotoxin, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).	RGPD4 RANBP2 RGPD8	4.54e-06	7	178	3	22821000
Pubmed	Complex genomic rearrangements lead to novel primate gene function.	RGPD4 RGPD8 RGPD5	4.54e-06	7	178	3	15710750
Pubmed	Genomic organization, expression, and localization of murine Ran-binding protein 2 (RanBP2) gene.	RGPD4 RANBP2 RGPD8	4.54e-06	7	178	3	11353387
Pubmed	Microglial activation in an amyotrophic lateral sclerosis-like model caused by Ranbp2 loss and nucleocytoplasmic transport impairment in retinal ganglion neurons.	RGPD4 RANBP2 RGPD8	4.54e-06	7	178	3	30944974
Pubmed	Nucleoporin Nup358 drives the differentiation of myeloid-biased multipotent progenitors by modulating HDAC3 nuclear translocation.	RGPD4 RANBP2 RGPD8	4.54e-06	7	178	3	38838144
Pubmed	Retina-specifically expressed novel subtypes of bovine cyclophilin.	RGPD4 RANBP2 RGPD8	4.54e-06	7	178	3	7559465
Pubmed	Mst1, RanBP2 and eIF4G are new markers for in vivo PI3K activation in murine and human prostate.	RGPD4 RANBP2 RGPD8	4.54e-06	7	178	3	17372272
Pubmed	Proteostatic Remodeling of Small Heat Shock Chaperones─Crystallins by Ran-Binding Protein 2─and the Peptidyl-Prolyl cis-trans Isomerase and Chaperone Activities of Its Cyclophilin Domain.	RGPD4 RANBP2 RGPD8	4.54e-06	7	178	3	38657106
Pubmed	Haploinsufficiency of RanBP2 is neuroprotective against light-elicited and age-dependent degeneration of photoreceptor neurons.	RGPD4 RANBP2 RGPD8	4.54e-06	7	178	3	18949001
Pubmed	Selective impairment of a subset of Ran-GTP-binding domains of ran-binding protein 2 (Ranbp2) suffices to recapitulate the degeneration of the retinal pigment epithelium (RPE) triggered by Ranbp2 ablation.	RGPD4 RANBP2 RGPD8	4.54e-06	7	178	3	25187515
Pubmed	Localization of the Ran-GTP binding protein RanBP2 at the cytoplasmic side of the nuclear pore complex.	RGPD4 RANBP2 RGPD8	4.54e-06	7	178	3	8603673
Pubmed	Uncoupling phototoxicity-elicited neural dysmorphology and death by insidious function and selective impairment of Ran-binding protein 2 (Ranbp2).	RGPD4 RANBP2 RGPD8	4.54e-06	7	178	3	26632511
Pubmed	Distinct and atypical intrinsic and extrinsic cell death pathways between photoreceptor cell types upon specific ablation of Ranbp2 in cone photoreceptors.	RGPD4 RANBP2 RGPD8	4.54e-06	7	178	3	23818861
Pubmed	Neuroprotection resulting from insufficiency of RANBP2 is associated with the modulation of protein and lipid homeostasis of functionally diverse but linked pathways in response to oxidative stress.	RGPD4 RANBP2 RGPD8	4.54e-06	7	178	3	20682751
Pubmed	mTORC2 interactome and localization determine aggressiveness of high-grade glioma cells through association with gelsolin.	MAPKAP1 RPN1 GART MCM6 TFRC PDIA4 MYOF IGF2R TLN1 SVIL	5.27e-06	312	178	10	37120454
Pubmed	Identifications of novel host cell factors that interact with the receptor-binding domain of the SARS-CoV-2 spike protein.	CUL3 MAPKAP1 PPP4R1 SMG1 WAPL PEX1 GON4L FHIP2A RGS3 IBTK YY1AP1 TANC1 GARRE1 RASAL2	7.23e-06	650	178	14	38777146
Pubmed	The nucleoporin RanBP2 tethers the cAMP effector Epac1 and inhibits its catalytic activity.	RGPD4 RANBP2 RGPD8	7.24e-06	8	178	3	21670213
Pubmed	Neutrophil-specific deletion of the CARD9 gene expression regulator suppresses autoantibody-induced inflammation in vivo.	MALT1 CARD9 PLCG2	7.24e-06	8	178	3	27032818
Pubmed	Critical role of RanBP2-mediated SUMOylation of Small Heterodimer Partner in maintaining bile acid homeostasis.	RGPD4 RANBP2 RGPD8	7.24e-06	8	178	3	27412403
Pubmed	Mice lacking Ran binding protein 1 are viable and show male infertility.	RGPD4 RANBP2 RGPD8	7.24e-06	8	178	3	21310149
Pubmed	The distribution of phosphorylated SR proteins and alternative splicing are regulated by RANBP2.	RGPD4 RANBP2 RGPD8	7.24e-06	8	178	3	22262462
Pubmed	Zap70 and downstream RanBP2 are required for the exact timing of the meiotic cell cycle in oocytes.	RGPD4 RANBP2 RGPD8	7.24e-06	8	178	3	28745977
Pubmed	Systematic analysis of human protein complexes identifies chromosome segregation proteins.	RGPD4 CUL3 RANBP2 WAPL PHF20 RGPD8 BSDC1 TACC2 CPS1 GDI2 GLCCI1 TASOR2 TFRC PDIA4 TLN1 SVIL CDC25C WDR62 RGPD5	8.24e-06	1155	178	19	20360068
Pubmed	The human cytoplasmic dynein interactome reveals novel activators of motility.	CUL3 RANBP2 AMER1 FXR2 IFT74 BSDC1 FHIP2A GDI2 IBTK CCDC66 IGF2R TLN1 SVIL TANC1 GARRE1 WDR62	9.00e-06	853	178	16	28718761
Pubmed	LukS-PV inhibits hepatocellular carcinoma cells migration by downregulating HDAC6 expression.	EPPK1 SYT3 RPN1 FXR2 IQSEC2 GART HRNR CPS1 ADD1 TFRC EFR3A PDIA4 SVIL	1.02e-05	580	178	13	35676659
Pubmed	Blocking an N-terminal acetylation-dependent protein interaction inhibits an E3 ligase.	CUL3 RPN1 GART RNF213 MCM6 ADGRV1 GDI2 PPM1B PDIA4 PPP4R2 FBXO7 CPVL	1.04e-05	495	178	12	28581483
Pubmed	Loss of Ranbp2 in motoneurons causes disruption of nucleocytoplasmic and chemokine signaling, proteostasis of hnRNPH3 and Mmp28, and development of amyotrophic lateral sclerosis-like syndromes.	RGPD4 RANBP2 RGPD8	1.08e-05	9	178	3	28100513
Pubmed	Association of the kinesin-binding domain of RanBP2 to KIF5B and KIF5C determines mitochondria localization and function.	RGPD4 RANBP2 RGPD8	1.08e-05	9	178	3	17887960
Pubmed	The cyclophilin-like domain mediates the association of Ran-binding protein 2 with subunits of the 19 S regulatory complex of the proteasome.	RGPD4 RANBP2 RGPD8	1.08e-05	9	178	3	9733766
Pubmed	Resolution of sister centromeres requires RanBP2-mediated SUMOylation of topoisomerase IIalpha.	RGPD4 RANBP2 RGPD8	1.08e-05	9	178	3	18394993
Pubmed	The docking of kinesins, KIF5B and KIF5C, to Ran-binding protein 2 (RanBP2) is mediated via a novel RanBP2 domain.	RGPD4 RANBP2 RGPD8	1.08e-05	9	178	3	11553612
Pubmed	The zinc finger cluster domain of RanBP2 is a specific docking site for the nuclear export factor, exportin-1.	RGPD4 RANBP2 RGPD8	1.08e-05	9	178	3	10601307
Pubmed	Impairments in age-dependent ubiquitin proteostasis and structural integrity of selective neurons by uncoupling Ran GTPase from the Ran-binding domain 3 of Ranbp2 and identification of novel mitochondrial isoforms of ubiquitin-conjugating enzyme E2I (ubc9) and Ranbp2.	RGPD4 RANBP2 RGPD8	1.08e-05	9	178	3	28877029
Pubmed	Defining the proximal interaction networks of Arf GTPases reveals a mechanism for the regulation of PLD1 and PI4KB.	AMER1 STON1 FERMT1 BSDC1 RNF213 HRNR ADD1 RYR2 TASOR2 FAT1 IGF2R KIDINS220 BRCA1 PCDH7 RASAL2	1.24e-05	777	178	15	35844135
Pubmed	Interactomes of Glycogen Synthase Kinase-3 Isoforms.	STON1 ADD1 IBTK KIDINS220 AKAP11 TANC1 RASAL2 WDR62	1.32e-05	209	178	8	36779422
Pubmed	KCTD13-mediated ubiquitination and degradation of GluN1 regulates excitatory synaptic transmission and seizure susceptibility.	CUL3 RAP1GDS1 SYT3 RPN1 PCLO IQSEC2 BCAN GDI2 SHANK3 ADD1 KIDINS220 C12orf50 PLPPR4 TLN1 SVIL TANC1 ALDH2 BSN CDH2 ATP2B2 RASAL2	1.51e-05	1431	178	21	37142655
Pubmed	Parkin ubiquitinates and promotes the degradation of RanBP2.	RGPD4 RANBP2 RGPD8	1.54e-05	10	178	3	16332688
Pubmed	The RanBP2/RanGAP1*SUMO1/Ubc9 SUMO E3 ligase is a disassembly machine for Crm1-dependent nuclear export complexes.	RGPD4 RANBP2 RGPD8	1.54e-05	10	178	3	27160050
Pubmed	Cyclophilin-related protein RanBP2 acts as chaperone for red/green opsin.	RGPD4 RANBP2 RGPD8	1.54e-05	10	178	3	8857542
Pubmed	Ran-dependent docking of importin-beta to RanBP2/Nup358 filaments is essential for protein import and cell viability.	RGPD4 RANBP2 RGPD8	1.54e-05	10	178	3	21859863
Pubmed	Synaptic GAP and GEF Complexes Cluster Proteins Essential for GTP Signaling.	CUL3 PCLO IQSEC2 GDI2 SHANK3 AKAP11 PCDH7 CDH10 RASAL2	1.58e-05	281	178	9	28706196
Pubmed	Large-scale proteomics and phosphoproteomics of urinary exosomes.	CUL3 RAP1GDS1 SERPINF1 NAGLU PM20D1 ADGRV1 GDI2 MYOF FAT1 IGF2R TLN1 ATP6V0A4 GATD1 ATP6V0D2 ALDH2 CPVL TMEM63A	2.04e-05	1016	178	17	19056867
Pubmed	SHANK proteins limit integrin activation by directly interacting with Rap1 and R-Ras.	KRAS SHANK3 TLN1	2.11e-05	11	178	3	28263956
Pubmed	RanBP2 modulates Cox11 and hexokinase I activities and haploinsufficiency of RanBP2 causes deficits in glucose metabolism.	RGPD4 RANBP2 RGPD8	2.11e-05	11	178	3	17069463
Pubmed	Transposable elements as a source of genetic innovation: expression and evolution of a family of retrotransposon-derived neogenes in mammals.	RTL8B RTL8A RTL8C	2.11e-05	11	178	3	15716091
Pubmed	T-cell receptor (TCR) signaling promotes the assembly of RanBP2/RanGAP1-SUMO1/Ubc9 nuclear pore subcomplex via PKC-θ-mediated phosphorylation of RanGAP1.	RGPD4 RANBP2 RGPD8	2.11e-05	11	178	3	34110283
Pubmed	A family of neofunctionalized Ty3/gypsy retrotransposon genes in mammalian genomes.	RTL8B RTL8A RTL8C	2.11e-05	11	178	3	16093683
Pubmed	An Rtn4/Nogo-A-interacting micropeptide modulates synaptic plasticity with age.	RGPD4 RANBP2 RGPD8	2.11e-05	11	178	3	35771867
Pubmed	ARMC5 is part of an RPB1-specific ubiquitin ligase implicated in adrenal hyperplasia.	CUL3 RPN1 GART MCM6 HRNR TFRC PDIA4	2.50e-05	166	178	7	35687106
Pubmed	Bassoon and Piccolo maintain synapse integrity by regulating protein ubiquitination and degradation.	PCLO BSN	2.60e-05	2	178	2	23403927
Pubmed	RAS interaction with Sin1 is dispensable for mTORC2 assembly and activity.	MAPKAP1 KRAS	2.60e-05	2	178	2	34380736
Pubmed	Concurrent PEDF deficiency and Kras mutation induce invasive pancreatic cancer and adipose-rich stroma in mice.	KRAS SERPINF1	2.60e-05	2	178	2	22234980
Pubmed	Role of Bassoon and Piccolo in Assembly and Molecular Organization of the Active Zone.	PCLO BSN	2.60e-05	2	178	2	26793095
Pubmed	Total synthesis of human relaxin and human relaxin derivatives by solid-phase peptide synthesis and site-directed chain combination.	RLN1 RLN2	2.60e-05	2	178	2	2040595
Pubmed	N-cadherin cleavage: A critical function that induces diabetic retinopathy fibrosis via regulation of β-catenin translocation.	SERPINF1 CDH2	2.60e-05	2	178	2	36939278
Pubmed	Structural characterization by mass spectrometry of native and recombinant human relaxin.	RLN1 RLN2	2.60e-05	2	178	2	2076464
Pubmed	Active zone density is conserved during synaptic growth but impaired in aged mice.	PCLO BSN	2.60e-05	2	178	2	21935939
Pubmed	BRCA1 represses amphiregulin gene expression.	AREG BRCA1	2.60e-05	2	178	2	20103632
Pubmed	The transcriptional regulator GON4L is required for viability and hematopoiesis in mice.	GON4L YY1AP1	2.60e-05	2	178	2	33864850
Pubmed	S-glutathionylation of an auxiliary subunit confers redox sensitivity to Kv4 channel inactivation.	KCND1 KCND2	2.60e-05	2	178	2	24675763
Pubmed	The Justy mutation identifies Gon4-like as a gene that is essential for B lymphopoiesis.	GON4L YY1AP1	2.60e-05	2	178	2	20530203
Pubmed	K-rasG12V mediated lung tumor models identified three new quantitative trait loci modifying events post-K-ras mutation.	KRAS RYR2	2.60e-05	2	178	2	25245290
Pubmed	Global gene expression analysis identifies molecular pathways distinguishing blastocyst dormancy and activation.	IGF2R BRCA1	2.60e-05	2	178	2	15232000
Pubmed	Downregulated METTL14 accumulates BPTF that reinforces super-enhancers and distal lung metastasis via glycolytic reprogramming in renal cell carcinoma.	METTL14 BPTF	2.60e-05	2	178	2	33664855
Pubmed	RNAi-mediated knockdown of relaxin decreases in vitro proliferation and invasiveness of osteosarcoma MG-63 cells by inhibition of MMP-9.	RLN1 RLN2	2.60e-05	2	178	2	23661525
Pubmed	A Mediator-cohesin axis controls heterochromatin domain formation.	WAPL MED12	2.60e-05	2	178	2	35136067
Pubmed	Oncogenic RAS isoforms show a hierarchical requirement for the guanine nucleotide exchange factor SOS2 to mediate cell transformation.	KRAS SOS2	2.60e-05	2	178	2	30181243
Pubmed	Dual-color STED microscopy reveals a sandwich structure of Bassoon and Piccolo in active zones of adult and aged mice.	PCLO BSN	2.60e-05	2	178	2	27321892
Pubmed	X-ray structure of human relaxin at 1.5 A. Comparison to insulin and implications for receptor binding determinants.	RLN1 RLN2	2.60e-05	2	178	2	1656049
Pubmed	Serum relaxin as a diagnostic and prognostic marker in patients with epithelial ovarian cancer.	RLN1 RLN2	2.60e-05	2	178	2	29060928
Pubmed	Blocking transferrin receptor inhibits the growth of lung adenocarcinoma cells in vitro.	KRAS TFRC	2.60e-05	2	178	2	29286585
Pubmed	The G protein signaling regulator RGS3 enhances the GTPase activity of KRAS.	KRAS RGS3	2.60e-05	2	178	2	34618566
Pubmed	S100PBP is regulated by mutated KRAS and plays a tumour suppressor role in pancreatic cancer.	KRAS S100PBP	2.60e-05	2	178	2	37794133
Pubmed	Piccolo and bassoon maintain synaptic vesicle clustering without directly participating in vesicle exocytosis.	PCLO BSN	2.60e-05	2	178	2	20332206
Pubmed	Newly identified Gon4l/Udu-interacting proteins implicate novel functions.	GON4L YY1AP1	2.60e-05	2	178	2	32848183
Pubmed	Relaxin, insulin and diabetes: an intriguing connection.	RLN1 RLN2	2.60e-05	2	178	2	22698078
Pubmed	Isolation and analysis of the 3'-untranslated regions of the human relaxin H1 and H2 genes.	RLN1 RLN2	2.60e-05	2	178	2	10750025
Pubmed	The relationship between expressions of the laminin gene and RET gene in Hirschsprung's disease.	LAMA1 RET	2.60e-05	2	178	2	18661771
Pubmed	Sequence-Selective Covalent CaaX-Box Receptors Prevent Farnesylation of Oncogenic Ras Proteins and Impact MAPK/PI3 K Signaling.	KRAS RTL8C	2.60e-05	2	178	2	33899342
Pubmed	Synaptic activity controls localization and function of CtBP1 via binding to Bassoon and Piccolo.	PCLO BSN	2.60e-05	2	178	2	25652077
Pubmed	Two human relaxin genes are on chromosome 9.	RLN1 RLN2	2.60e-05	2	178	2	6548703
Interaction	RGPD2 interactions	RGPD4 RANBP2 RGPD8 ADARB1 RGPD5	3.50e-06	27	178	5	int:RGPD2
Interaction	SS18L2 interactions	KRAS RAP1GDS1 BICRA GON4L FBXO7 YY1AP1 CPVL	4.88e-06	76	178	7	int:SS18L2
Interaction	LCMT1 interactions	CUL3 FXR2 BRCA1 EIF1AX PPP4R2	9.87e-06	33	178	5	int:LCMT1
Interaction	YWHAE interactions	CUL3 MAPKAP1 KRAS RAP1GDS1 DOCK11 DOCK9 IQSEC2 COL6A5 TACC2 PFKFB4 GLCCI1 RGS3 SHANK3 PPM1B PDIA4 BRCA1 SVIL AKAP11 TANC1 CDK11B ALDH2 DOT1L CDC25C PCDH7 GARRE1 RASAL2 WDR62	1.58e-05	1256	178	27	int:YWHAE
Interaction	NPIPB6 interactions	KRAS RANBP2 RGPD8 RGPD5	1.63e-05	18	178	4	int:NPIPB6
GeneFamily	Protein phosphatase 4 regulatory subunits	PPP4R1 PPP4R2	1.44e-04	3	126	2	698
GeneFamily	Cadherin related	RET FAT1 FAT2	2.09e-04	17	126	3	24
GeneFamily	Fibronectin type III domain containing\|USH2 complex	PDZD7 ADGRV1	2.86e-04	4	126	2	1244
GeneFamily	Tetratricopeptide repeat domain containing\|Bardet-Biedl syndrome associated\|BBSome	RGPD4 RANBP2 RGPD8 TANC1 RGPD5	1.26e-03	115	126	5	769
GeneFamily	Pleckstrin homology domain containing\|Rho guanine nucleotide exchange factors\|C2 domain containing	RPGRIP1 PCLO RGS3	1.99e-03	36	126	3	823
Coexpression	DACOSTA_UV_RESPONSE_VIA_ERCC3_DN	RANBP2 WAPL PHF20 DOCK9 ADARB1 PPM1B EFR3A BPTF MALT1 MYOF IBTK FAT1 IGF2R KIDINS220 BRCA1 AKAP11 CDH2 GARRE1 SOS2	5.38e-06	856	176	19	M4500
Coexpression	TABULA_MURIS_SENIS_TRACHEA_GRANULOCYTE_AGEING	RGPD4 RANBP2 RGPD8 PPP4R2 GARRE1	1.01e-05	43	176	5	MM3857
Coexpression	DEBIASI_APOPTOSIS_BY_REOVIRUS_INFECTION_DN	PEX1 TFRC PDIA4 IGF2R BRCA1 IPO13 PLCG2 PCDH7 NOTCH3 TMEM63A	1.86e-05	276	176	10	M3063
Coexpression	WONG_ADULT_TISSUE_STEM_MODULE	ACOX1 PCLO SERPINF1 ESAM RRAD ADARB1 SHANK3 RYR2 IGSF10 IGF2R KCND2 NFIX SENP6 NKX3-1 CDH2 PLXNA2	3.09e-05	721	176	16	M1999
Coexpression	MANNO_MIDBRAIN_NEUROTYPES_HRGL1	STON1 WNT8B HEATR5A BCAN ADGRV1 FAT1 FAT2 BRCA1 COL21A1 CDC25C ATP2B2	3.79e-05	364	176	11	M39057
Coexpression	NAKAYA_PBMC_FLUARIX_FLUVIRIN_AGE_18_50YO_3DY_DN	KRAS RANBP2 RGPD8 PTBP2 FHIP2A USP16 PPM1B TASOR2 TFRC BTG1 CDK11B RGPD5	3.81e-05	432	176	12	M41149
Coexpression	HE_LIM_SUN_FETAL_LUNG_C0_PERICYTE	NAB1 GJC1 ESAM RRAD MYOF EGFLAM TANC1 NOTCH3	5.44e-05	195	176	8	M45684
Coexpression	NAKAYA_PBMC_FLUMIST_AGE_18_50YO_3DY_DN	CUL3 PPP4R1 KRAS RANBP2 RGPD8 PTBP2 BSDC1 MCM6 USP16 PPM1B METTL14 CCDC66 PPP4R2 KIF25 RGPD5	5.89e-05	680	176	15	M41089
Coexpression	GSE29618_LAIV_VS_TIV_FLU_VACCINE_DAY7_PDC_UP	PPP4R1 PTBP2 ADD1 TFRC UBP1 SENP6 ALDH2 MED12	6.06e-05	198	176	8	M5018
Coexpression	GSE360_T_GONDII_VS_B_MALAYI_LOW_DOSE_MAC_DN	PHF20 ACOX1 IQSEC2 NAGLU PPM1B PDIA4 FBXO7 TMEM63A	6.28e-05	199	176	8	M5257
Coexpression	GSE360_CTRL_VS_L_DONOVANI_DC_DN	CHL1 ACOX1 IQSEC2 MC2R EIF1AX BTG1 ATP2B2 WDR62	6.50e-05	200	176	8	M5144
Coexpression	GAUSSMANN_MLL_AF4_FUSION_TARGETS_B_UP	RGPD4 RANBP2 RGPD8 BTG1	6.90e-05	33	176	4	MM477
Coexpression	GSE21063_CTRL_VS_ANTI_IGM_STIM_BCELL_8H_UP	CHL1 KRAS NAB1 LAMA1 PDZD7 MALT1 TMEM63A	8.12e-05	153	176	7	M8249
Coexpression	MANNO_MIDBRAIN_NEUROTYPES_HNBGABA	CHL1 RFK GPR12 TMC7 PCLO PDZD7 RYR2 PLPPR4 KCND2 RALGPS1 ZFHX2 BSN ATP2B2 PCDH7 PLXNA2	8.54e-05	703	176	15	M39070
ToppCell	NS-moderate-d_0-4\|moderate / Location, Severity, dps_group, Lineage and Cell class of Upper airway (combined)	CHL1 DNAH3 ADGRV1 IGSF10 EFHC1 COL21A1 NFIX HSD17B13 PCDH7 PLXNA2 DRC3	4.02e-10	193	179	11	ea345d34440b25f65358a53dc72831998d1c3620
ToppCell	LPS-IL1RA-Stromal_mesenchymal-Matrix_Fibroblast-MatrixFB\|LPS-IL1RA / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	CHL1 SERPINF1 COL6A5 ADARB1 RYR2 IGSF10 MYOF COL21A1 PCDH7 CDH10	6.11e-09	192	179	10	deeecd26972241846b4cb998edf0c7a87ff0c4df
ToppCell	LPS_IL1RA-Mesenchymal_fibroblastic-Fibroblasts-MatrixFB\|LPS_IL1RA / Treatment groups by lineage, cell group, cell type	CHL1 SERPINF1 LAMA1 COL6A5 ADARB1 RYR2 IGSF10 MYOF COL21A1 CDH10	8.61e-09	199	179	10	a7dd94b172c973a131a6792f8ccd9bfe44d984ac
ToppCell	LPS-IL1RA+antiTNF-Stromal_mesenchymal\|LPS-IL1RA+antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	CHL1 SERPINF1 COL6A5 ADARB1 RYR2 IGSF10 MYOF COL21A1 PCDH7	8.83e-08	192	179	9	3d0cb19f037f604253d7d728689aeaa94251e92b
ToppCell	TCGA-Prostate-Primary_Tumor-Prostate_Adenocarcinoma-Acinar_Adenocarcinoma-6\|TCGA-Prostate / Sample_Type by Project: Shred V9	RANBP2 ACTR8 HEATR5A ADGRV1 TASOR2 EFR3A BPTF IGF2R LRRC8B	9.23e-08	193	179	9	abd71b2cf667ef2b1c4d88acd0c1dd19a12ff659
ToppCell	LPS_anti-TNF-Mesenchymal_fibroblastic-Fibroblasts-Activated_MatrixFB\|LPS_anti-TNF / Treatment groups by lineage, cell group, cell type	CHL1 SERPINF1 COL6A5 ADARB1 RYR2 IGSF10 MYOF COL21A1 BSN	1.10e-07	197	179	9	fdb92985f7df0c280b87d3e43c2394e70786a2c7
ToppCell	LA-13._Vascular_Smooth_Muscle\|LA / Chamber and Cluster_Paper	ADARB1 RYR2 MYOF COL21A1 SVIL PCDH7 RASAL2 NOTCH3	9.71e-07	188	179	8	34e1b074a3995aa46ab194eb45115d76d1a5514d
ToppCell	LPS-IL1RA+antiTNF-Stromal_mesenchymal-Matrix_Fibroblast-Diff_MatrixFB\|LPS-IL1RA+antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	CHL1 SERPINF1 COL6A5 ADARB1 IGSF10 COL21A1 PCDH7 CDH10	1.05e-06	190	179	8	841cd55861b43578d704418b9bc0af2e8b88323a
ToppCell	tumor_Lung-Myeloid_cells-CD207+CD1a+_LCs\|Myeloid_cells / Location, Cell class and cell subclass	CHL1 ALX3 SERPINF1 ESAM GDI2 CARD9 COL21A1 CPVL	1.05e-06	190	179	8	58a6ab70737d719ca9725ac087f20dfe9be0463e
ToppCell	LPS-IL1RA+antiTNF-Stromal_mesenchymal-Matrix_Fibroblast-Activated_MatrixFB\|LPS-IL1RA+antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	CHL1 SERPINF1 COL6A5 ADARB1 RYR2 IGSF10 COL21A1 PCDH7	1.09e-06	191	179	8	b13229bb7f3713a392271aaf5dbae3edd1b9fe5a
ToppCell	LPS-IL1RA-Stromal_mesenchymal-Matrix_Fibroblast\|LPS-IL1RA / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	CHL1 SERPINF1 COL6A5 ADARB1 RYR2 IGSF10 MYOF PCDH7	1.14e-06	192	179	8	f4fc2b0121f879bab2bee99dfb5ff2c3ca1c0e1b
ToppCell	PCW_10-12-Mesenchymal-Mesenchymal_myocytic-mes_pericyte_(14)\|PCW_10-12 / Celltypes from embryonic and fetal-stage human lung	DOCK11 GJC1 ESAM RRAD RYR2 KCND2 EGFLAM NOTCH3	1.14e-06	192	179	8	5000440dc1ed17e7474d340921bdff945646f27e
ToppCell	10x5'v1-week_17-19-Mesenchymal_osteo-stroma-early_osteoblast\|week_17-19 / cell types per 3 fetal stages;per 3',per 5'	SYT12 RGS3 FAT1 EGFLAM TANC1 CDH2 PCDH7 NOTCH3	1.18e-06	193	179	8	5e46a9f65e85aca78f825fdef88a95b97eec8743
ToppCell	LPS-IL1RA+antiTNF-Stromal_mesenchymal-Matrix_Fibroblast-MatrixFB\|LPS-IL1RA+antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	CHL1 SERPINF1 COL6A5 ADARB1 IGSF10 COL21A1 PCDH7 CDH10	1.18e-06	193	179	8	fb28717fadd06c3840636d25409ce80c9254bd34
ToppCell	LPS-antiTNF-Stromal_mesenchymal\|LPS-antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	CHL1 SERPINF1 COL6A5 ADARB1 RYR2 IGSF10 MYOF PCDH7	1.23e-06	194	179	8	6e13549f697f7478b34fe71f7dd9d63c5d3db22e
ToppCell	LPS-antiTNF-Stromal_mesenchymal-Matrix_Fibroblast-MatrixFB\|LPS-antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	CHL1 SERPINF1 COL6A5 ADARB1 IGSF10 COL21A1 PCDH7 CDH10	1.23e-06	194	179	8	60622bd2f75bfe4c37f721cb12f03dab33f2f58d
ToppCell	wk_15-18-Mesenchymal-Myofibro_&_SMC-Pericyte\|wk_15-18 / Celltypes from embryonic and fetal-stage human lung	NAB1 GJC1 ESAM RRAD RGS3 EGFLAM TANC1 NOTCH3	1.43e-06	198	179	8	76d46950c11cb4708866db0da54ce00d5c0adab8
ToppCell	LPS_anti-TNF-Mesenchymal_fibroblastic-Fibroblasts-MatrixFB\|LPS_anti-TNF / Treatment groups by lineage, cell group, cell type	CHL1 SERPINF1 LAMA1 COL6A5 IGSF10 MYOF COL21A1 CDH10	1.54e-06	200	179	8	9b0916d8d07ac2bf1739f7be5296bf77ffee6094
ToppCell	Control-NK\|World / Disease group and Cell class	IQSEC2 AREG NFIX GTF2IRD2 CDH2 RASAL2 RGPD5	1.86e-06	143	179	7	fe08adc9472dfd4242497d6c614d0490713261da
ToppCell	facs-Marrow-B-cells-24m-Lymphocytic-precursor_B_cell\|Marrow / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation	KCTD19 LAMA1 COL6A5 ADGRV1 CPS1 RYR2 CPVL	3.92e-06	160	179	7	c381ec6be8cf887861cc18f831a20db42f953fe1
ToppCell	facs-Marrow-B-cells-24m-Lymphocytic-pre_B_cell\|Marrow / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation	KCTD19 LAMA1 COL6A5 ADGRV1 CPS1 RYR2 CPVL	3.92e-06	160	179	7	25c8f3d2a6d14ff0ca0b965fce89d3ff22f40585
ToppCell	368C-Lymphocytic-NK_cells-NK_cell_C\|368C / Donor, Lineage, Cell class and subclass (all cells)	DOCK11 ATAD5 BICRA PDZD7 ZFHX2 RGPD5 S100PBP	5.40e-06	168	179	7	0372c06b70f0ba95bf8cd1363ca7c5f31207f094
ToppCell	Children_(3_yrs)-Mesenchymal-vascular_smooth_muscle_cell\|Children_(3_yrs) / Lineage, Cell type, age group and donor	GJC1 RRAD HRNR ADARB1 RYR2 COL21A1 NOTCH3	6.55e-06	173	179	7	5416b092321c7d9b63f0418c60f2402a138355bf
ToppCell	PND07-Mesenchymal-Mesenchymal_myocytic-Myofibroblast_vascular-VSMC-VSMC_prolif\|PND07 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif	MCM6 RRAD RYR2 BRCA1 DOT1L PCDH7 NOTCH3	6.80e-06	174	179	7	9f2e253694eb5860c00528fda31c305c6de8a2a1
ToppCell	E16.5-Mesenchymal-Mesenchymal_myocytic-Myofibroblast_vascular-Pericyte-Pericyte_G2M\|E16.5 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif	KCTD19 GJC1 IGF2R CARD9 EGFLAM CDH2 NOTCH3	7.06e-06	175	179	7	fa16c6ba08dc0cc22e8cf049db0577811d080df6
ToppCell	5'-Airway_Nasal-Epithelial-Airway_ciliated-ciliated_columnar_cell_of_tracheobronchial_tree-Multiciliated_(non-nasal)-\|5' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	CFAP276 PFKFB4 HRNR TASOR2 DYDC1 ZFHX2 DRC3	7.33e-06	176	179	7	87de432c680b80555342afac864599bbc002c040
ToppCell	368C-Lymphocytic-NK_cells-NK_cell_E\|Lymphocytic / Donor, Lineage, Cell class and subclass (all cells)	PCLO RRAD AREG EFHC1 CARD9 COL21A1 CCDC171	7.61e-06	177	179	7	946803293a7955116c80f403e99e4093e798ca3f
ToppCell	356C-Fibroblasts-Fibroblast-G\|356C / Donor, Lineage, Cell class and subclass (all cells)	PLCD4 COL6A5 BCAN RYR2 PLPPR4 KCND1 COL21A1	7.61e-06	177	179	7	8220cc2fc0ee8764a67a3be51d75248be2453040
ToppCell	356C-Fibroblasts-Fibroblast-G-\|356C / Donor, Lineage, Cell class and subclass (all cells)	PLCD4 COL6A5 BCAN RYR2 PLPPR4 KCND1 COL21A1	7.61e-06	177	179	7	7617270f49cd6b7ba66db72d20560cee985012b2
ToppCell	Striatum-Endothelial-MURAL\|Striatum / BrainAtlas - Mouse McCarroll V32	ALX3 STON1 GJC1 ESAM RRAD EGFLAM NOTCH3	8.19e-06	179	179	7	3d58babf44e47462c3d4129dd2e94a2339fd7ce0
ToppCell	ASK454-Endothelial-Lymphatic\|ASK454 / Donor, Lineage and Cell class of Lung cells from Dropseq	RPGRIP1 DNAH3 RAP1GDS1 GON4L PFKFB4 PCDH7 GARRE1	8.19e-06	179	179	7	fd84a79f76a01c0377dff5b20016b004d369f96f
ToppCell	PND03-Mesenchymal-Mesenchymal_myocytic-Myofibroblast_vascular-Pericyte-Pericyte_mature\|PND03 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif	GJC1 RRAD IGF2R CARD9 EGFLAM CDH2 NOTCH3	8.19e-06	179	179	7	56db12467b445f2b8ef92af50779eeab10413eb2
ToppCell	Striatum-Endothelial-MURAL-M1(Rgs5Acta2)\|Striatum / BrainAtlas - Mouse McCarroll V32	ALX3 STON1 GJC1 ESAM RRAD EGFLAM NOTCH3	8.19e-06	179	179	7	99167ac678cae5c35b1d4f4a81b32000437c00c2
ToppCell	P15-Mesenchymal-developing_mesenchymal_cell-mesenchymal_myogenic_precursor_(Axin2+)\|P15 / developmental_time, Lineage, Cell group, Cell type, Cell type_cellcyc-phase	GJC1 PFKFB4 RRAD CARD9 EGFLAM CDH2 NOTCH3	1.01e-05	185	179	7	b1e84228c95be8ccf7c3c1afb66b71ffb93cf61e
ToppCell	facs-Skin-Anagen-3m-Epithelial-nan\|Skin / Skin_Bladder_Kidney_Mammary_Gland - method, tissue, subtissue, age, lineage, cell ontology and free annotation	CHL1 RPN1 NAB1 GART CYP51A1 CHIT1 PDIA4	1.05e-05	186	179	7	9a7932d0a208f3997216bd21a72913cc82b59fc9
ToppCell	5'-GW_trimst-2-LymphNode-Mesenchymal-Pericytes-angiogenic_pericyte\|GW_trimst-2 / Celltypes from developing, pediatric, Crohn's, & adult GI tract	ALX3 GJC1 ESAM RRAD PLPPR4 EGFLAM NOTCH3	1.09e-05	187	179	7	b8f88599e22b9b345c7ec3bbecd87a8b2a033f9f
ToppCell	Fetal_29-31_weeks-Mesenchymal-pericyte_cell\|Fetal_29-31_weeks / Lineage, Cell type, age group and donor	GJC1 RRAD RYR2 MYOF EGFLAM TANC1 NOTCH3	1.09e-05	187	179	7	a2bf958ea59c359a265bfa437d59315e1920cdd4
ToppCell	Fetal_29-31_weeks-Epithelial-alveolar_epithelial_cell_type_1-D088\|Fetal_29-31_weeks / Lineage, Cell type, age group and donor	RAP1GDS1 TMC7 AREG MYOF DOT1L PLXNA2 RASAL2	1.13e-05	188	179	7	43a3a59f92ad93509d4166bd025aed0b1b39a008
ToppCell	E17.5-Mesenchymal-developing_mesenchymal_cell-mesenchymal_myogenic_precursor_(Axin2+)\|E17.5 / developmental_time, Lineage, Cell group, Cell type, Cell type_cellcyc-phase	GJC1 RRAD IGF2R CARD9 EGFLAM CDH2 NOTCH3	1.17e-05	189	179	7	26cfe5b7e7f477f225f4e9f25f983f432f01e183
ToppCell	LPS-antiTNF-Stromal_mesenchymal-Matrix_Fibroblast-Diff_MatrixFB\|LPS-antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	CHL1 SERPINF1 COL6A5 ADARB1 IGSF10 COL21A1 PCDH7	1.17e-05	189	179	7	a153b83314cf52808f685296cff8c95af3f4983d
ToppCell	Striatum-Endothelial\|Striatum / BrainAtlas - Mouse McCarroll V32	ALX3 STON1 GJC1 ESAM RRAD EGFLAM NOTCH3	1.17e-05	189	179	7	95ee3b6d7fbbfcf91c780dfcd0926acec05f0a2d
ToppCell	LPS_only-Stromal_mesenchymal-Matrix_Fibroblast-MatrixFB\|LPS_only / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	CHL1 SERPINF1 COL6A5 ADARB1 RYR2 MYOF PCDH7	1.17e-05	189	179	7	2a22b9fae70afb3dab8476f9c00e48a4df756410
ToppCell	PND03-Mesenchymal-Mesenchymal_myocytic-Myofibroblast_vascular-Pericyte\|PND03 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif	GJC1 RRAD IGF2R CARD9 EGFLAM CDH2 NOTCH3	1.17e-05	189	179	7	ca3a04c202afc32aa11d17154066ef7dc6d01405
ToppCell	E17.5-Mesenchymal-developing_mesenchymal_cell\|E17.5 / developmental_time, Lineage, Cell group, Cell type, Cell type_cellcyc-phase	GJC1 RRAD IGF2R CARD9 EGFLAM CDH2 NOTCH3	1.21e-05	190	179	7	2ab604d35456beba71c25511e0f819000e6642d2
ToppCell	RV-15._Ventricular_Cardiomyocyte_III\|RV / Chamber and Cluster_Paper	TACC2 RYR2 FAT1 SVIL TANC1 CDH2 PCDH7	1.21e-05	190	179	7	93c3188dfeb0b2f9889f8ae9b9c1f2f34129c99b
ToppCell	E18.5-Mesenchymal-Mesenchymal_myocytic-Myofibroblast_vascular-Pericyte-Pericyte_mature\|E18.5 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif	GJC1 RRAD IGF2R CARD9 EGFLAM CDH2 NOTCH3	1.21e-05	190	179	7	951e067d14412db67dc3babcdf61e41717d7b429
ToppCell	LPS_only-Stromal_mesenchymal-Matrix_Fibroblast\|LPS_only / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	CHL1 SERPINF1 COL6A5 ADARB1 RYR2 MYOF PCDH7	1.29e-05	192	179	7	ee085e04d5dcfb657522484ed20b8c1ddeccfe0c
ToppCell	LPS-IL1RA+antiTNF-Stromal_mesenchymal-Matrix_Fibroblast\|LPS-IL1RA+antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	CHL1 SERPINF1 COL6A5 ADARB1 IGSF10 COL21A1 PCDH7	1.29e-05	192	179	7	6f4ef24dab544681304b7f8a9dc073e7edaa4cf5
ToppCell	LPS-antiTNF-Stromal_mesenchymal-Matrix_Fibroblast\|LPS-antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	CHL1 SERPINF1 COL6A5 ADARB1 IGSF10 COL21A1 PCDH7	1.29e-05	192	179	7	dcd924d6eb67d33ee9f5d3e8ab6e1d4283d6b708
ToppCell	LPS_only-Stromal_mesenchymal\|LPS_only / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	CHL1 SERPINF1 COL6A5 ADARB1 RYR2 MYOF PCDH7	1.29e-05	192	179	7	162d8b5858d150ecbbd1c9bf2b19c6c9cd50a158
ToppCell	COPD-Stromal-Myofibroblast\|Stromal / Disease state, Lineage and Cell class	ADARB1 RGS3 RYR2 COL21A1 TANC1 PCDH7 PLXNA2	1.29e-05	192	179	7	62904f94dfce430456f05066522cbf9bd29f4d7e
ToppCell	wk_20-22-Mesenchymal-Myofibro_&_SMC-Vascular_SMC_1\|wk_20-22 / Celltypes from embryonic and fetal-stage human lung	NAB1 GJC1 ESAM RRAD FAT1 COL21A1 NOTCH3	1.34e-05	193	179	7	ba6eb29478d16589172f48f9992e5116328c81d6
ToppCell	LPS-antiTNF-Stromal_mesenchymal-Matrix_Fibroblast-Activated_MatrixFB\|LPS-antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	CHL1 SERPINF1 COL6A5 ADARB1 IGSF10 MYOF PCDH7	1.38e-05	194	179	7	89b706af2b25991fc2707eb24f49ba6ff3ae01f7
ToppCell	3'-Airway_Nasal-Epithelial-Airway_ciliated-multi-ciliated_epithelial_cell-Multiciliated_(nasal)-Multiciliated_(nasal)_L.0.3.1.1\|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	DNAH3 CFAP276 RRAD EFHC1 ATP6V0A4 HSD17B13 DRC3	1.43e-05	195	179	7	79dc031258579ea328181dda33710dd897f1064a
ToppCell	facs-Lung-nan-3m-Endothelial\|Lung / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation	DOCK9 ESAM TTPAL SHANK3 GARRE1 PLXNA2 RASAL2	1.43e-05	195	179	7	7f9b7f15006610ad591063d90e90367bd6083c7f
ToppCell	LPS_IL1RA_TNF\|World / Treatment groups by lineage, cell group, cell type	CHL1 SERPINF1 COL6A5 PDIA4 IGSF10 MYOF COL21A1	1.52e-05	197	179	7	0a6550dce156fc81f15b1e7830d331ca50d87d06
ToppCell	ILEUM-inflamed-(8)_Pericytes\|inflamed / shred on tissue, inflammation_status, cell class(v3), cell subclass (v2)	SERPINF1 GJC1 ESAM FAT1 PLPPR4 EGFLAM NOTCH3	1.52e-05	197	179	7	e04ac8575f66d798ddf2fd6d55d397a163b40732
ToppCell	10x3'2.3-week_14-16-Mesenchymal_osteo-stroma-osteoblast_precursor\|week_14-16 / cell types per 3 fetal stages;per 3',per 5'	STON1 RGS3 FAT1 TANC1 CDH2 PCDH7 NOTCH3	1.58e-05	198	179	7	9d61483b0decac2fe90045b3474843360b2c49b3
ToppCell	wk_08-11-Mesenchymal-Myofibro_&_SMC-Pericyte\|wk_08-11 / Celltypes from embryonic and fetal-stage human lung	NAB1 GJC1 ESAM RRAD RGS3 EGFLAM NOTCH3	1.58e-05	198	179	7	72aad5b2dcd8b0bde58828fa4f8129fe6cb6a21d
ToppCell	3'-Broncho-tracheal-Epithelial-Airway_epithelium-respiratory_basal_cell-Basal_resting-Basal_resting_L.0.0.0.2\|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	CHL1 SERPINF1 MYOF FAT1 FAT2 PLCG2 PCDH7	1.58e-05	198	179	7	fc00cb25cdc6c31b7f9d397bc9f9a8f4e9708003
ToppCell	Smart-start-Cell-Wel_seq-Non-neoplastic-Glial-Neuronal-OPC-OPC\|Smart-start-Cell-Wel_seq / Platform, Oncotype, Lineage, Cell_class, celltype (level4), mutation group	CHL1 DOCK9 CYP51A1 TACC2 BCAN PCDH7 CDH10	1.63e-05	199	179	7	e60ecbb8fa7bcd3e2ce7d78f6efb2cfd1fd77698
ToppCell	LPS_IL1RA-Mesenchymal_fibroblastic-Fibroblasts-Activated_MatrixFB\|LPS_IL1RA / Treatment groups by lineage, cell group, cell type	CHL1 SERPINF1 COL6A5 RYR2 IGSF10 MYOF COL21A1	1.63e-05	199	179	7	8b86c69aaf60feff53aa782559cfece7342a23de
ToppCell	Smart-start-Cell-Wel_seq-Non-neoplastic-Glial-Neuronal-OPC\|Smart-start-Cell-Wel_seq / Platform, Oncotype, Lineage, Cell_class, celltype (level4), mutation group	CHL1 DOCK9 CYP51A1 TACC2 BCAN PCDH7 CDH10	1.63e-05	199	179	7	333056c2abe9724efeab542c0365fcfe4eff8f18
ToppCell	COVID-19-COVID-19_Mild-Myeloid-immature_Neutrophil\|COVID-19_Mild / Disease, condition lineage and cell class	DNAH3 MCM6 CCDC168 CHIT1 IGSF10 C12orf50 TANC1	1.63e-05	199	179	7	e222b90caf45904d8f763574e7b6aac13333df92
ToppCell	(02)_MMP9/10+-(2)_GFP_FOXI1\|(02)_MMP9/10+ / shred by cell type by condition	RFK STON1 USP16 GLCCI1 BPTF MAN1A2 PCDH7	1.63e-05	199	179	7	18a7f9ced4364f45b184bd529f32ef02c27779d3
ToppCell	Tracheal-10x5prime-Endothelial-Endothelia_vascular-VE_systemic_arterial\|10x5prime / Cell types per location group and 10X technology with lineage, and cell group designations	DOCK9 ESAM SHANK3 PLCG2 ATP2B2 GARRE1 PLXNA2	1.68e-05	200	179	7	5ec31c1be6bcc4124e1489d136570f3de33cc2e9
ToppCell	Parenchyma_Control_(B.)-Stromal-TX-Fibroblasts-1\|Parenchyma_Control_(B.) / Sample group, Lineage and Cell type	COL6A5 ADARB1 RYR2 IGSF10 PLPPR4 COL21A1 PCDH7	1.68e-05	200	179	7	aa1a35dcca3b799241eef4237f6eb94660e019f0
ToppCell	Lung_Parenchyma-Control-Mesenchymal-Mesenchymal-Fibroblasts-1\|Control / Location, Disease Group, Cell group, Cell class (2021.03.09)	COL6A5 ADARB1 RYR2 IGSF10 PLPPR4 COL21A1 PCDH7	1.68e-05	200	179	7	a510deaada669e690329183e18df02870bd204b3
ToppCell	LPS_only-Mesenchymal_fibroblastic-Fibroblasts-MatrixFB\|LPS_only / Treatment groups by lineage, cell group, cell type	CHL1 SERPINF1 LAMA1 COL6A5 RYR2 MYOF COL21A1	1.68e-05	200	179	7	a7ef7022b8efcaedb7319b0b43d8c4e99d788fe2
ToppCell	Control_saline-Mesenchymal_myocytic-Pericyte-Pericyte_2\|Control_saline / Treatment groups by lineage, cell group, cell type	DOCK11 GJC1 RYR2 FAT1 LRRC8B CDH2 NOTCH3	1.68e-05	200	179	7	bc8949eb34482aca166c4602ff6ab876cb4c2c3c
ToppCell	5'-GW_trimst-1.5-SmallIntestine-Neuronal-Glial_immature-ENCC/glia_Progenitor\|GW_trimst-1.5 / Celltypes from developing, pediatric, Crohn's, & adult GI tract	CHL1 GPR12 BCAN ADGRV1 FBXO7 EGFLAM CDH2	1.68e-05	200	179	7	de55100e98d3e9b8a74e37aebcd3afa2b0996527
ToppCell	Lung_Parenchyma-Control-Mesenchymal-Mesenchymal-Fibroblasts-1-\|Control / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01)	COL6A5 ADARB1 RYR2 IGSF10 PLPPR4 COL21A1 PCDH7	1.68e-05	200	179	7	dd4228cbed8a4395166a6332e08d44d88bebe3b9
ToppCell	Cerebellum-Endothelial-MURAL-M1(Rgs5Acta2)-M1_2\|Cerebellum / BrainAtlas - Mouse McCarroll V32	BICRA CCDC168 RRAD SENP6 CCDC171 NOTCH3	1.95e-05	137	179	6	9324b55eac55e0cc1e8e450a4b5374d12e9587a3
ToppCell	Cerebellum-Endothelial-MURAL-M1(Rgs5Acta2)-M1_2-MURAL_Mural.Acta2Rgs5.Kcnj8_(Mural.Acta2Rgs5.Kcnj8)\|Cerebellum / BrainAtlas - Mouse McCarroll V32	BICRA CCDC168 RRAD SENP6 CCDC171 NOTCH3	1.95e-05	137	179	6	032f8409d0d179e254c8ff632afbda78852a9889
ToppCell	Cerebellum-Endothelial-MURAL-M1(Rgs5Acta2)-M1_2-MURAL_Mural.Acta2Rgs5.Kcnj8_(Mural.Acta2Rgs5.Kcnj8)-\|Cerebellum / BrainAtlas - Mouse McCarroll V32	BICRA CCDC168 RRAD SENP6 CCDC171 NOTCH3	1.95e-05	137	179	6	265a4a50e48b13c8b3b0730f818235f71fbd6baa
ToppCell	Brain_organoid-organoid_Kanton_Nature-Organoid-4M-Neuronal-cortical_neurons_1\|Organoid-4M / Sample Type, Dataset, Time_group, and Cell type.	SYT12 COL6A5 SHANK3 MMP25 DYDC1 RTL8B	2.29e-05	141	179	6	73b3e967357cba7585d97ec9e9d48d3e94ebe31e
ToppCell	renal_medulla_nuclei-CKD+DKD_normotensive-Epithelial-Collecting_tubule_epithelial_cell-kidney_collecting_duct_intercalated_cell-Intercalated_Cell_Type_B\|CKD+DKD_normotensive / Celltypes from Cells and Nuclei per compartment and clinical group	MMP25 RTL8B ATP6V0A4 ATP6V0D2 PLCG2 BSN	3.13e-05	149	179	6	61d84838a841ed2d6b8c5f86d423a4e6b3dcc9cb
ToppCell	Hippocampus-Endothelial-MURAL\|Hippocampus / BrainAtlas - Mouse McCarroll V32	ALX3 GJC1 ESAM RRAD EGFLAM NOTCH3	4.34e-05	158	179	6	2d73b5e59c650c603fec6223b1c51f0962f7bc81
ToppCell	Hippocampus-Endothelial-MURAL-M1(Rgs5Acta2)\|Hippocampus / BrainAtlas - Mouse McCarroll V32	ALX3 GJC1 ESAM RRAD EGFLAM NOTCH3	4.34e-05	158	179	6	7f4a644534b78f7e7539cae1fd895dad6f96862b
ToppCell	356C-Fibroblasts-Fibroblast-G-\|Fibroblasts / Donor, Lineage, Cell class and subclass (all cells)	SMG1 PLCD4 COL6A5 GLCCI1 RGS3 RYR2	4.66e-05	160	179	6	0293b244c063a62819690bf22bbc2681f8d15252
ToppCell	356C-Fibroblasts-Fibroblast-G\|Fibroblasts / Donor, Lineage, Cell class and subclass (all cells)	SMG1 PLCD4 COL6A5 GLCCI1 RGS3 RYR2	4.66e-05	160	179	6	3eaae86fa08f7651021316f8e5811bf48055591e
ToppCell	Frontal_cortex-Endothelial-MURAL-M1(Rgs5Acta2)-M1_3\|Frontal_cortex / BrainAtlas - Mouse McCarroll V32	NAB1 MC2R RRAD CPVL NOTCH3	4.98e-05	99	179	5	8aab2a6989d342af387bd0823f79e7b326a12430
ToppCell	Control-APC-like-Monocytes\|Control / group, cell type (main and fine annotations)	TDRD5 RGPD8 FXR2 PFKFB4 RET EIF1AY	5.16e-05	163	179	6	4bc80a2c741d462724b6f3902377d48c57478932
ToppCell	control-Epithelial-Ionocyte\|control / Severity, Lineage and Cell class of Nasopharyngeal (NS) Samples from Patients and Controls	RET RLN1 ATP6V0A4 ATP6V0D2 PLCG2 CDH2	5.52e-05	165	179	6	5cfba9a46bd8ceeca74a6493057b4d38af6b06fe
ToppCell	ICU-NoSEP-Myeloid-cDC2\|ICU-NoSEP / Disease, Lineage and Cell Type	TMC7 SERPINF1 AREG FAT2 ALDH2 CPVL	5.91e-05	167	179	6	5b7b731944d888591279ef6167b3ae8cab3f6886
ToppCell	E18.5-Mesenchymal-Mesenchymal_myocytic-Myofibroblast_vascular-Pericyte-Pericyte_prolif\|E18.5 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif	GJC1 RRAD IGF2R CARD9 CDH2 NOTCH3	5.91e-05	167	179	6	b0eb7a40491dd2432f5282f578ce569df86d21a7
ToppCell	control-Epithelial-Ionocyte\|Epithelial / Severity, Lineage and Cell class of Nasopharyngeal (NS) Samples from Patients and Controls	RET RLN1 ATP6V0A4 ATP6V0D2 PLCG2 CDH2	6.11e-05	168	179	6	327b02f19f4a8607c033203824fdc60a1254331f
ToppCell	PBMC_fresh-frozen-Mild-Moderate_progression_d02_child-Lymphocytic-Lymphocytic_T-mature_alpha-beta_T_cell-T_CD4_c03-ITGA4\|Mild-Moderate_progression_d02_child / Compartment, severity and other cell annotations on 10x 3' data (130k)	RPGRIP1 SERPINF1 RGS3 NKX3-1 MED12 NOTCH3	6.11e-05	168	179	6	ca94b29c1030484143a77f2df06dad74d2c6136e
ToppCell	PBMC-Severe-Myeloid-cDC-cDC-cDC_12\|Severe / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01)	SERPINF1 MCM6 AREG ATP6V0D2 ALDH2 CPVL	7.18e-05	173	179	6	9c7386bf0a899882c733f0b4921a96afde032a7d
ToppCell	PBMC-Severe-Myeloid-cDC-cDC-cDC_12\|Severe / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.09)	SERPINF1 MCM6 AREG ATP6V0D2 ALDH2 CPVL	7.18e-05	173	179	6	a55f310c533432e9e26e400026a5b47245152976
ToppCell	renal_medulla_nuclei-CKD+DKD_normotensive-Epithelial-Collecting_tubule_epithelial_cell-kidney_collecting_duct_intercalated_cell\|CKD+DKD_normotensive / Celltypes from Cells and Nuclei per compartment and clinical group	CHL1 FAM184B GLCCI1 ATP6V0A4 ATP6V0D2 PLCG2	7.65e-05	175	179	6	1d8da48236549c01381f777ce5b2937f9f86acc2
ToppCell	renal_cortex_nuclei-Renal_AKI_(acute_kidney_injury)-Epithelial-Collecting_tubule_epithelial_cell-kidney_collecting_duct_intercalated_cell-Cortical_Collecting_Duct_Intercalated_Cell_Type_A\|Renal_AKI_(acute_kidney_injury) / Celltypes from Cells and Nuclei per compartment and clinical group	CHL1 FAM184B GLCCI1 ATP6V0A4 ATP6V0D2 PLCG2	7.65e-05	175	179	6	98947a226b5a2ac7091ff9d34243ea7736add973
ToppCell	renal_cortex_nuclei-Adult_normal_reference-Epithelial-Collecting_tubule_epithelial_cell-kidney_collecting_duct_intercalated_cell-Outer_Medullary_Collecting_Duct_Intercalated_Cell_Type_A\|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group	CHL1 FAM184B ATP6V0A4 ATP6V0D2 PLCG2 KIF25	7.90e-05	176	179	6	cb21342dd135cc80a50aafe7bf8bf31265db68dd
ToppCell	droplet-Heart-nan-3m\|Heart / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation	RANBP2 STON1 RYR2 IGSF10 IBTK PCDH7	7.90e-05	176	179	6	749b47eac5436fa34e0d243ffbc6f1897f4e431e
ToppCell	droplet-Lung-3m-Mesenchymal-myofibroblast-pericyte_cell\|3m / method, tissue, age, lineage, sublineage, cell ontologies, cell type and subtype	GJC1 RRAD CARD9 EGFLAM CDH2 NOTCH3	7.90e-05	176	179	6	f931192e3cc65414e2245354f443473696cc7ce8
ToppCell	renal_medulla_nuclei-Hypertensive_with+without-CKD-Epithelial-Collecting_tubule_epithelial_cell-kidney_collecting_duct_intercalated_cell-Cortical_Collecting_Duct_Intercalated_Cell_Type_A\|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group	CHL1 FAM184B GLCCI1 ATP6V0A4 ATP6V0D2 PLCG2	7.90e-05	176	179	6	c2c4306476989bc2fb30dab00250ef7915842f13
ToppCell	droplet-Lung-3m-Mesenchymal-myofibroblast-pericyte_cell-pericyte\|3m / method, tissue, age, lineage, sublineage, cell ontologies, cell type and subtype	GJC1 RRAD CARD9 EGFLAM CDH2 NOTCH3	7.90e-05	176	179	6	e2b59a904c5c8f9c88e1e63788e9b6485f22edd0
ToppCell	nucseq-Epithelial-Epithelial_Airway-Basal/Suprabasal\|nucseq / Celltype signatures by Technology, Lineage, Lineage_subclass, Celltype_group, Cell_type2	CHL1 SERPINF1 FERMT1 FAT2 CDH2 PCDH7	8.15e-05	177	179	6	cbad1a23851151dbef01ea2af960e6f0944f838b
ToppCell	facs-Heart-RV-18m-Mesenchymal-valve_cell\|Heart / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation	SYT12 GJC1 PLCD4 EFHC1 EGFLAM NOTCH3	8.15e-05	177	179	6	7c3d46ebd7e8726be6871aa9763e281fc0ec6ac8
ToppCell	facs-Heart-RV-18m-Mesenchymal-valve_cell\|Heart / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation	SYT12 GJC1 PLCD4 EFHC1 EGFLAM NOTCH3	8.15e-05	177	179	6	e7b1f3092e6b8d0d580f82648035f5ad12be6961
Drug	Cyclopenthiazide [742-20-1]; Down 200; 10.6uM; PC3; HT_HG-U133A	KRAS ATAD5 BICRA ACOX1 NAB1 GJC1 GON4L ZNF34 PLPPR4 SENP6 CDC25C TMEM63A	4.36e-08	195	177	12	4229_DN
Drug	Ascorbic acid [50-81-7]; Down 200; 22.4uM; MCF7; HT_HG-U133A	BICRA SERPINF1 ADARB1 BBS9 RYR2 EIF1AY MMP25 MYOF SVIL RASAL2 TMEM63A	4.30e-07	197	177	11	3225_DN
Drug	DITPA	RET RYR2 KCND2 CPVL MED12	1.01e-06	24	177	5	CID000160565
Drug	nordihydroguaiaretic acid; Down 200; 1uM; HL60; HT_HG-U133A	KRAS RFK BICRA TAF1B FERMT1 NAGLU MAN1A2 KIDINS220 UBP1 SVIL	3.29e-06	196	177	10	1164_DN
Drug	Forskolin, from Coleus forskohlii; Down 200; 0.5uM; MCF7; HT_HG-U133A	STON1 TMC7 ATAD5 IQSEC2 BBS9 RGS3 RYR2 PCDH7 TMEM63A SOS2	3.29e-06	196	177	10	7055_DN
Drug	Phenylpropanolamine hydrochloride [154-41-6]; Down 200; 21.4uM; MCF7; HT_HG-U133A	TMC7 BICRA SERPINF1 IQSEC2 ADARB1 WDR59 RALGPS1 PCDH7 TMEM63A SOS2	3.29e-06	196	177	10	3217_DN
Drug	Tolmetin sodium salt dihydrate [64490-92-2]; Down 200; 12.6uM; PC3; HT_HG-U133A	KRAS NAB1 PEX1 ADARB1 BBS9 RYR2 PLPPR4 LRRC8B PLXNA2 TMEM63A	3.93e-06	200	177	10	4088_DN
Drug	Sanguinarine [2447-54-3]; Down 200; 12uM; MCF7; HT_HG-U133A	ACTR8 FXR2 ATAD5 PCLO MYOF MAN1A2 AKAP11 LRRC8B RASAL2	1.94e-05	191	177	9	4168_DN
Drug	Bucladesine sodium salt [16980-89-5]; Down 200; 7.8uM; HL60; HT_HG-U133A	KRAS ACTR8 NAB1 RGS3 MAN1A2 RTL8A CDC25C WDR62 TMEM63A	2.20e-05	194	177	9	2741_DN
Drug	Amethopterin (R,S) [59-05-2]; Down 200; 8.8uM; PC3; HT_HG-U133A	STON1 ATAD5 BICRA ADD1 RYR2 SVIL SENP6 ALDH2 CDC25C	2.29e-05	195	177	9	6654_DN
Drug	Picrotoxinin [17617-45-7]; Down 200; 13.6uM; PC3; HT_HG-U133A	KRAS RFK NAB1 CPS1 ADARB1 ZNF34 SENP6 CDC25C SOS2	2.29e-05	195	177	9	4260_DN
Drug	chlorpromazine hydrochloride; Up 200; 1uM; MCF7; HT_HG-U133A	DOCK9 SERPINF1 IQSEC2 ADARB1 RYR2 ZNF34 ATP2B2 PLXNA2 KIF25	2.38e-05	196	177	9	5577_UP
Drug	Dioxybenzone [131-53-3]; Down 200; 16.4uM; HL60; HT_HG-U133A	RFK STON1 PHF20 PCLO WDR59 MMP25 SENP6 RTL8A SOS2	2.38e-05	196	177	9	3101_DN
Drug	Pridinol methanesulfonate salt [6856-31-1]; Down 200; 10.2uM; PC3; HT_HG-U133A	EPPK1 FXR2 GART ZNF34 MYOF TLN1 LRRC8B NOTCH3 TMEM63A	2.38e-05	196	177	9	5860_DN
Drug	Sulfadoxine [2447-57-6]; Up 200; 12.8uM; PC3; HT_HG-U133A	CUL3 EPPK1 FXR2 NAB1 BCAN COL21A1 SENP6 CDH10 SOS2	2.38e-05	196	177	9	5852_UP
Drug	Mesoridazine besylate [32672-69-8]; Down 200; 7.4uM; MCF7; HT_HG-U133A	DNAH3 ATAD5 PTBP2 IFT74 NAGLU PDIA4 NKX3-1 NOTCH3 SOS2	2.38e-05	196	177	9	7017_DN
Drug	Trapidil [15421-84-8]; Up 200; 19.4uM; MCF7; HT_HG-U133A	PHF20 TMC7 ADARB1 BBS9 RYR2 MALT1 NKX3-1 CDH10 TMEM63A	2.58e-05	198	177	9	7475_UP
Drug	Clenbuterol hydrochloride [21898-19-1]; Down 200; 12.8uM; MCF7; HT_HG-U133A	STON1 FXR2 PCLO SERPINF1 BBS9 EIF1AY KIDINS220 LRRC8B TMEM63A	2.58e-05	198	177	9	5266_DN
Drug	Ornidazole [16773-42-5]; Up 200; 18.2uM; PC3; HT_HG-U133A	MC2R PFKFB4 ADARB1 RYR2 MMP25 ATP2B2 PCDH7 NOTCH3 TMEM63A	2.58e-05	198	177	9	5064_UP
Drug	Ginkgolide A [15291-75-5]; Up 200; 9.8uM; MCF7; HT_HG-U133A	SYT12 WDR59 ZNF34 MYOF KIDINS220 ATP6V0A4 LRRC8B RASAL2 SOS2	2.58e-05	198	177	9	3260_UP
Drug	alpha-Santonin [481-06-1]; Down 200; 16.2uM; PC3; HT_HG-U133A	KRAS DNAH3 STON1 IQSEC2 NAGLU BBS9 RYR2 BRCA1 TMEM63A	2.68e-05	199	177	9	4531_DN
Drug	Trichlormethiazide [133-67-5]; Down 200; 10.6uM; MCF7; HT_HG-U133A	KRAS FXR2 ACOX1 IQSEC2 PEX1 RGS3 EIF1AY MYOF KIDINS220	2.79e-05	200	177	9	4783_DN
Drug	dibromoacetonitrile	ACOX1 BCAN MALT1	7.28e-05	11	177	3	CID000018617
Drug	LY 294002; Up 200; 10uM; MCF7; HT_HG-U133A	STON1 SERPINF1 IQSEC2 RGS3 MYOF BTG1 LRRC8B CDC25C	9.23e-05	182	177	8	1661_UP
Drug	Rifabutin [72559-06-9]; Up 200; 4.8uM; PC3; HT_HG-U133A	STON1 RLN1 PLPPR4 COL21A1 NKX3-1 PCDH7 RASAL2 KIF25	9.96e-05	184	177	8	4527_UP
Drug	Lycorine hydrochloride [2188-68-3]; Down 200; 12.4uM; MCF7; HT_HG-U133A	MAPKAP1 STON1 SYT12 RET EIF1AY MAN1A2 RALGPS1 TMEM63A	1.03e-04	185	177	8	4365_DN
Drug	LY 294002; Up 200; 10uM; MCF7; HT_HG-U133A	STON1 PCLO IQSEC2 MYOF MAN1A2 RALGPS1 BTG1 SOS2	1.11e-04	187	177	8	5233_UP
Drug	17-AAG; Down 200; 1uM; MCF7; HT_HG-U133A_EA	RFK ACOX1 TAF1B RET PPM1B TFRC BPTF S100PBP	1.24e-04	190	177	8	1044_DN
Drug	Isoproterenol	KRAS STON1 SYT12 RPN1 IFT74 DOCK9 NAB1 BSDC1 TACC2 RRAD CPS1 RYR2 FETUB TFRC PDIA4 CKM KCND2 IPO13 ALDH2 CDH2	1.31e-04	1016	177	20	ctd:D007545
Drug	clozapine; Down 200; 10uM; HL60; HT_HG-U133A	KRAS PHF20 BBS9 RYR2 LRRC8B RTL8A WDR62 TMEM63A	1.34e-04	192	177	8	6188_DN
Drug	Selegiline hydrochloride [14611-52-0]; Up 200; 17.8uM; MCF7; HT_HG-U133A	DOCK9 PCLO BBS9 RYR2 KCND1 ALDH2 CDH2 KIF25	1.39e-04	193	177	8	4146_UP
Drug	Ketanserin tartrate hydrate [83846-83-7]; Down 200; 7uM; MCF7; HT_HG-U133A	IQSEC2 GART ADARB1 WDR59 RYR2 SENP6 RASAL2 SOS2	1.39e-04	193	177	8	3209_DN
Drug	Cefalonium [5575-21-3]; Up 200; 8.8uM; MCF7; HT_HG-U133A	STON1 BBS9 RGS3 RLN1 ZNF34 MALT1 MAN1A2 SOS2	1.39e-04	193	177	8	7341_UP
Drug	(-) -Levobunolol hydrochloride [27912-14-7]; Down 200; 12.2uM; MCF7; HT_HG-U133A	PHF20 IQSEC2 RYR2 RLN1 EIF1AY MAN1A2 KIDINS220 RASAL2	1.44e-04	194	177	8	4134_DN
Drug	Tridihexethyl chloride; Up 200; 11.4uM; MCF7; HT_HG-U133A	KRAS FXR2 BICRA DOCK9 SERPINF1 CARD9 NOTCH3 TMEM63A	1.44e-04	194	177	8	3526_UP
Drug	Flumethasone [2135-17-3]; Up 200; 9.8uM; MCF7; HT_HG-U133A	KRAS FXR2 DOCK9 RYR2 MAN1A2 CDH2 PLXNA2 RASAL2	1.49e-04	195	177	8	4734_UP
Drug	Gibberellic acid [77-06-5]; Down 200; 11.6uM; PC3; HT_HG-U133A	KRAS ADARB1 SENP6 PLCG2 ALDH2 CDC25C CDH10 SOS2	1.49e-04	195	177	8	4234_DN
Drug	trifluoperazine dihydrochloride; Up 200; 10uM; MCF7; HG-U133A	GON4L PPM1B KIDINS220 BTG1 ALDH2 NOTCH3 TMEM63A SOS2	1.49e-04	195	177	8	421_UP
Drug	SB 202190; Down 200; 1uM; MCF7; HT_HG-U133A	STON1 TMC7 ATAD5 RGS3 WDR59 RYR2 PCDH7 SOS2	1.49e-04	195	177	8	7054_DN
Drug	Nalidixic acid sodium salt hydrate; Down 200; 14.6uM; HL60; HT_HG-U133A	KRAS TMC7 GON4L PDZD7 RYR2 MAN1A2 TLN1 SVIL	1.49e-04	195	177	8	2336_DN
Drug	Sulfadiazine [68-35-9]; Up 200; 16uM; HL60; HT_HG-U133A	DNAH3 ACOX1 BSDC1 PPM1B MYOF RTL8C CPVL TMEM63A	1.54e-04	196	177	8	1852_UP
Drug	Scoulerine [6451-73-6]; Down 200; 12.2uM; PC3; HT_HG-U133A	PHF20 ATAD5 PCLO WDR59 NFIX SENP6 LRRC8B SOS2	1.54e-04	196	177	8	5111_DN
Drug	Ozagrel hydrochloride [78712-43-3]; Down 200; 15.2uM; HL60; HT_HG-U133A	CUL3 DNAH3 PHF20 BCAN WDR59 RYR2 RASAL2 TMEM63A	1.54e-04	196	177	8	2942_DN
Drug	Hydrocortisone base [50-23-7]; Down 200; 11uM; PC3; HT_HG-U133A	KRAS ACTR8 PHF20 ATAD5 PLCG2 ALDH2 PLXNA2 WDR62	1.54e-04	196	177	8	6684_DN
Drug	Catechin-(+,-) hydrate [7295-85-4]; Down 200; 13.8uM; MCF7; HT_HG-U133A	STON1 IFT74 IQSEC2 EIF1AY MMP25 PCDH7 GARRE1 RASAL2	1.54e-04	196	177	8	3351_DN
Drug	Epicatechin-(-) [154-23-4]; Down 200; 13.8uM; MCF7; HT_HG-U133A	BICRA IQSEC2 CPS1 RGS3 RYR2 ZFHX2 TMEM63A SOS2	1.54e-04	196	177	8	4419_DN
Drug	Paromomycin sulfate [1263-89-4]; Down 200; 5.6uM; MCF7; HT_HG-U133A	KRAS ATAD5 SERPINF1 ADARB1 RGS3 LRRC8B TMEM63A SOS2	1.54e-04	196	177	8	4420_DN
Drug	Midecamycin [35457-80-8]; Down 200; 5uM; PC3; HT_HG-U133A	ATAD5 NAB1 CPS1 TLN1 SENP6 PLCG2 CDC25C SOS2	1.54e-04	196	177	8	6745_DN
Drug	Miconazole [22916-47-8]; Up 200; 9.6uM; PC3; HT_HG-U133A	MC2R PFKFB4 WDR59 ADD1 MMP25 PLPPR4 CDC25C RASAL2	1.54e-04	196	177	8	6615_UP
Drug	Hydrastine hydrochloride [5936-28-7]; Down 200; 9.6uM; MCF7; HT_HG-U133A	DNAH3 SYT12 FXR2 BICRA IQSEC2 MALT1 SVIL WDR62	1.59e-04	197	177	8	6011_DN
Drug	clozapine; Up 200; 10uM; MCF7; HT_HG-U133A	BBS9 RYR2 FETUB KIDINS220 MED12 RASAL2 TMEM63A SOS2	1.59e-04	197	177	8	6988_UP
Drug	Desipramine hydrochloride [58-28-6]; Down 200; 13.2uM; MCF7; HT_HG-U133A	SYT12 FXR2 ADARB1 ZNF34 BRCA1 RASAL2 TMEM63A SOS2	1.59e-04	197	177	8	3212_DN
Drug	Beta-Escin [11072-93-8]; Down 200; 3.2uM; PC3; HT_HG-U133A	ACTR8 DOCK9 GJC1 BBS9 BRCA1 CDC25C CDH10 TMEM63A	1.59e-04	197	177	8	4544_DN
Drug	Cefotaxime sodium salt [64485-93-4]; Down 200; 8.4uM; MCF7; HT_HG-U133A	IFT74 GON4L ADARB1 EIF1AY ZNF34 KIDINS220 WDR62 TMEM63A	1.59e-04	197	177	8	2235_DN
Drug	Sulfachloropyridazine [80-32-0]; Down 200; 14uM; PC3; HT_HG-U133A	ATAD5 IQSEC2 ADARB1 NFIX SVIL SENP6 NOTCH3 SOS2	1.59e-04	197	177	8	3769_DN
Drug	Cortisone [53-06-5]; Down 200; 11uM; MCF7; HT_HG-U133A	FXR2 FERMT1 BSDC1 BBS9 WDR59 IPO13 PLCG2 TMEM63A	1.59e-04	197	177	8	7458_DN
Drug	Stachydrine hydrochloride; Down 200; 22.2uM; MCF7; HT_HG-U133A	DNAH3 PHF20 TMC7 IQSEC2 BBS9 EIF1AY RALGPS1 SOS2	1.59e-04	197	177	8	6805_DN
Drug	Succinylsulfathiazole [116-43-8]; Down 200; 11.2uM; PC3; HT_HG-U133A	KRAS ADARB1 BBS9 MAN1A2 PLPPR4 SENP6 RASAL2 SOS2	1.59e-04	197	177	8	4265_DN
Drug	Fluocinonide [356-12-7]; Down 200; 8uM; MCF7; HT_HG-U133A	ACTR8 WAPL ATAD5 FERMT1 NAGLU ADD1 RALGPS1 GARRE1	1.65e-04	198	177	8	3414_DN
Drug	Oxethazaine [126-27-2]; Up 200; 8.6uM; MCF7; HT_HG-U133A	MC2R BCAN RYR2 RALGPS1 ATP6V0A4 PCDH7 TMEM63A SOS2	1.65e-04	198	177	8	1484_UP
Drug	Guanfacine hydrochloride [29110-48-3]; Down 200; 14.2uM; MCF7; HT_HG-U133A	IFT74 IQSEC2 ZNF34 KIDINS220 SENP6 RASAL2 NOTCH3 SOS2	1.65e-04	198	177	8	5621_DN
Drug	Diprophylline [479-18-5]; Up 200; 15.8uM; MCF7; HT_HG-U133A	FXR2 WNT8B GART BBS9 MMP25 ZNF34 RASAL2 TMEM63A	1.65e-04	198	177	8	1689_UP
Drug	Fluocinonide [356-12-7]; Up 200; 8uM; MCF7; HT_HG-U133A	SERPINF1 BBS9 RYR2 MYOF IPO13 RASAL2 WDR62 SOS2	1.65e-04	198	177	8	3414_UP
Drug	Azathioprine [446-86-6]; Up 200; 14.4uM; PC3; HT_HG-U133A	STON1 ATAD5 ADARB1 SENP6 ZFHX2 CDH10 WDR62 SOS2	1.65e-04	198	177	8	4667_UP
Drug	Gliquidone [33342-05-1]; Down 200; 7.6uM; MCF7; HT_HG-U133A	KRAS BCAN MYOF KIDINS220 BRCA1 CDH10 MED12 TMEM63A	1.65e-04	198	177	8	6505_DN
Drug	Bacampicillin hydrochloride [37661-08-8]; Down 200; 8uM; PC3; HT_HG-U133A	STON1 ATAD5 GON4L ADARB1 WDR59 ZNF34 SVIL PLXNA2	1.65e-04	198	177	8	4592_DN
Drug	Methocarbamol [532-03-6]; Down 200; 16.6uM; MCF7; HT_HG-U133A	STON1 ADARB1 BBS9 RGS3 EIF1AY MYOF TLN1 SOS2	1.65e-04	198	177	8	2274_DN
Drug	GBR 12909 dihydrochloride [67469-78-7]; Down 200; 7.6uM; PC3; HT_HG-U133A	KRAS DNAH3 CPS1 WDR59 EIF1AY CDC25C ATP2B2 CDH10	1.71e-04	199	177	8	4641_DN
Drug	Famotidine [76824-35-6]; Down 200; 11.8uM; PC3; HT_HG-U133A	EPPK1 TMC7 FXR2 ATAD5 IQSEC2 BBS9 SENP6 PLCG2	1.71e-04	199	177	8	6665_DN
Drug	Baclofen (R,S) [1134-47-0]; Down 200; 18.8uM; MCF7; HT_HG-U133A	PEX1 BBS9 RGS3 WDR59 MALT1 MYOF RASAL2 WDR62	1.71e-04	199	177	8	1536_DN
Drug	Natamycin [7681-93-8]; Down 200; 6uM; PC3; HT_HG-U133A	RFK EPPK1 GART ADD1 BPTF SENP6 RTL8A TMEM63A	1.71e-04	199	177	8	5809_DN
Drug	SR-95639A [115767-94-7]; Down 200; 10uM; PC3; HT_HG-U133A	FXR2 IQSEC2 BCAN BBS9 EIF1AY COL21A1 SENP6 WDR62	1.71e-04	199	177	8	6632_DN
Drug	Zuclopenthixol hydrochloride [633-59-0]; Down 200; 9.2uM; PC3; HT_HG-U133A	KRAS FXR2 ATAD5 NAB1 PEX1 PLPPR4 SENP6 CDC25C	1.71e-04	199	177	8	4261_DN
Drug	ICI182,780; Up 200; 1uM; MCF7; HT_HG-U133A	STON1 IFT74 BCAN BBS9 MMP25 GARRE1 WDR62 TMEM63A	1.71e-04	199	177	8	6872_UP
Drug	Atropine-N-oxide hydrochloride [4574-60-1]; Down 200; 11.8uM; MCF7; HT_HG-U133A	DNAH3 SYT12 SERPINF1 RYR2 MYOF KIDINS220 RASAL2 SOS2	1.71e-04	199	177	8	2216_DN
Drug	Phenethicillin potassium salt [132-93-4]; Up 200; 10uM; HL60; HT_HG-U133A	ACOX1 PCLO PFKFB4 CPS1 SENP6 NKX3-1 CDC25C WDR62	1.77e-04	200	177	8	2542_UP
Drug	CAY10397; Up 200; 10uM; MCF7; HT_HG-U133A	MC2R BSDC1 ADARB1 MALT1 MYOF RALGPS1 ZFHX2 TMEM63A	1.77e-04	200	177	8	7082_UP
Drug	Pralidoxime chloride [51-15-0]; Up 200; 23.2uM; PC3; HT_HG-U133A	FXR2 ADD1 KIDINS220 BRCA1 SVIL CDH10 RASAL2 SOS2	1.77e-04	200	177	8	6283_UP
Disease	serum gamma-glutamyl transferase measurement	KRAS SYT12 DOCK11 BICRA NAGLU GON4L CPS1 USP16 RYR2 BPTF TLN1 SVIL HACE1 HSD17B13 YY1AP1 ALDH2 CCDC171	2.32e-05	914	170	17	EFO_0004532
Disease	Usher syndrome, type 2C	PDZD7 ADGRV1	3.30e-05	2	170	2	C2931213
Disease	USHER SYNDROME, TYPE IIC	PDZD7 ADGRV1	3.30e-05	2	170	2	605472
Disease	uveal melanoma (implicated_via_orthology)	EIF1AY EIF1AX	3.30e-05	2	170	2	DOID:6039 (implicated_via_orthology)
Disease	salivary gland cancer (implicated_via_orthology)	GON4L YY1AP1	3.30e-05	2	170	2	DOID:8850 (implicated_via_orthology)
Disease	Usher syndrome type 2C	PDZD7 ADGRV1	3.30e-05	2	170	2	cv:C2931213
Disease	Usher syndrome type 2C (is_implicated_in)	PDZD7 ADGRV1	3.30e-05	2	170	2	DOID:0110839 (is_implicated_in)
Disease	Intellectual Disability	CHL1 LAMA1 NAGLU GON4L FHIP2A SHANK3 BPTF BRCA1 NXF5 CDH2 WDR62	6.10e-05	447	170	11	C3714756
Disease	high grade glioma (implicated_via_orthology)	KRAS BCAN AREG WDR62	1.21e-04	44	170	4	DOID:3070 (implicated_via_orthology)
Disease	Profound Mental Retardation	CHL1 LAMA1 NAGLU GON4L SHANK3 WDR62	1.60e-04	139	170	6	C0020796
Disease	Mental Retardation, Psychosocial	CHL1 LAMA1 NAGLU GON4L SHANK3 WDR62	1.60e-04	139	170	6	C0025363
Disease	Mental deficiency	CHL1 LAMA1 NAGLU GON4L SHANK3 WDR62	1.60e-04	139	170	6	C0917816
Disease	Transitional cell carcinoma of bladder	KRAS RET	1.96e-04	4	170	2	C0279680
Disease	Squamous cell carcinoma of esophagus	GDI2 FAT1 FAT2 ALDH2 NOTCH3	2.28e-04	95	170	5	C0279626
Disease	cortical thickness	STON1 PTBP2 DOCK9 LAMA1 MUS81 PM20D1 TACC2 ADGRV1 BBS9 COL21A1 NFIX RALGPS1 CCDC171 CPVL PCDH7 PLXNA2 SOS2	2.53e-04	1113	170	17	EFO_0004840
Disease	Prostatic Neoplasms	CUL3 KRAS RFK SERPINF1 NAGLU MC2R RLN2 IGF2R BRCA1 SENP6 NKX3-1 MED12	2.53e-04	616	170	12	C0033578
Disease	Malignant neoplasm of prostate	CUL3 KRAS RFK SERPINF1 NAGLU MC2R RLN2 IGF2R BRCA1 SENP6 NKX3-1 MED12	2.53e-04	616	170	12	C0376358
Disease	post-operative atrial fibrillation, response to surgery	STON1 ADGRV1	3.26e-04	5	170	2	EFO_0009951, EFO_0009952
Disease	post-operative stroke, response to surgery	BBS9 RYR2	3.26e-04	5	170	2	EFO_0009951, EFO_0009956
Disease	Malignant neoplasm of thyroid	KRAS RET	3.26e-04	5	170	2	C0007115
Disease	HIRSCHSPRUNG DISEASE, SUSCEPTIBILITY TO, 1	RET MED12	4.88e-04	6	170	2	C3888239
Disease	amyotrophic lateral sclerosis (is_marker_for)	SERPINF1 ADARB1 BPTF	6.15e-04	29	170	3	DOID:332 (is_marker_for)
Disease	parental longevity	MAPKAP1 BICRA PCLO MC2R CPS1 IGF2R ALDH2 BSN CCDC171 CDH2	6.19e-04	494	170	10	EFO_0007796
Disease	prostate cancer (implicated_via_orthology)	KRAS CYP51A1 NKX3-1	9.03e-04	33	170	3	DOID:10283 (implicated_via_orthology)
Disease	Ventricular Dysfunction	IGF2R ALDH2	9.03e-04	8	170	2	C0242973
Disease	Pancreatic carcinoma, familial	KRAS BRCA1	1.16e-03	9	170	2	C2931038
Disease	neuroimaging measurement	DOCK9 NAGLU GJC1 PM20D1 TACC2 BCAN BBS9 GLCCI1 TFRC BRCA1 NFIX RALGPS1 CPVL PCDH7 PLXNA2	1.38e-03	1069	170	15	EFO_0004346
Disease	arrhythmogenic right ventricular cardiomyopathy (is_implicated_in)	RYR2 CDH2	1.44e-03	10	170	2	DOID:0050431 (is_implicated_in)
Disease	obesity (implicated_via_orthology)	GPR12 ADARB1 ZFHX2 ALDH2 MED12 NOTCH3	1.59e-03	215	170	6	DOID:9970 (implicated_via_orthology)
Disease	Combined immunodeficiency	TFRC MALT1 DCLRE1C	1.71e-03	41	170	3	C0494261
Disease	Hirschsprung's disease (is_implicated_in)	WNT8B RET	1.75e-03	11	170	2	DOID:10487 (is_implicated_in)
Disease	hip geometry	ADGRV1 CCDC66 CDH2	2.09e-03	44	170	3	EFO_0004685
Disease	Non-Small Cell Lung Carcinoma	KRAS RET RRAD AREG NOTCH3	2.15e-03	156	170	5	C0007131
Disease	Benign tumor of pancreas	KRAS BRCA1	2.47e-03	13	170	2	C0347284
Disease	body weight	ATAD5 BSDC1 GON4L ADGRV1 RET CPS1 GLCCI1 WDR59 EFR3A BPTF HACE1 SENP6 DOT1L CCDC171 CPVL PCDH7	2.65e-03	1261	170	16	EFO_0004338
Disease	psychosis	COL21A1 CPVL	2.87e-03	14	170	2	EFO_0005407
Disease	smoking status measurement	CUL3 MAPKAP1 SYT3 BICRA PDZD7 ADARB1 ADD1 RYR2 BPTF MAN1A2 KCND2 HACE1 CCDC171 CDH2 PLXNA2	3.01e-03	1160	170	15	EFO_0006527
Disease	generalised epilepsy	NAB1 RYR2 PCDH7	3.38e-03	52	170	3	EFO_0005917
Disease	platelet crit	FAM184B DNAH3 STON1 ADGRV1 CPS1 KCND1 NFIX TLN1 SVIL ALDH2 DOT1L RASAL2 NOTCH3	3.60e-03	952	170	13	EFO_0007985
Disease	Myocardial Ischemia	AREG RYR2 PPM1B TFRC CDH2	3.60e-03	176	170	5	C0151744
Disease	neutrophil measurement	EPPK1 RPN1 GLCCI1 FAT2 TMEM63A	3.69e-03	177	170	5	EFO_0803548
Disease	Herpes Zoster	TMC7 HACE1	4.24e-03	17	170	2	EFO_0006510
Disease	blood urea nitrogen measurement	DOCK9 GON4L PLCD4 MCM6 ADGRV1 CPS1 TANC1 CCDC171	4.85e-03	452	170	8	EFO_0004741
Disease	reaction time measurement	PTBP2 ESAM PM20D1 TACC2 EFR3A NFIX ALDH2 CCDC171 CDH2 PLXNA2	5.00e-03	658	170	10	EFO_0008393
Disease	Noonan-Like Syndrome With Loose Anagen Hair	KRAS SOS2	5.29e-03	19	170	2	C3501846
Disease	Pancreatic carcinoma	KRAS BRCA1	5.29e-03	19	170	2	C0235974
Disease	Noonan syndrome-like disorder with loose anagen hair	KRAS SOS2	5.29e-03	19	170	2	C1843181
Disease	Cardio-facio-cutaneous syndrome	KRAS SOS2	5.29e-03	19	170	2	C1275081
Disease	Costello syndrome (disorder)	KRAS SOS2	5.29e-03	19	170	2	C0587248
Disease	Omenn Syndrome	TFRC DCLRE1C	5.29e-03	19	170	2	C2700553
Disease	leukemia (implicated_via_orthology)	KRAS DOT1L	5.29e-03	19	170	2	DOID:1240 (implicated_via_orthology)
Disease	colorectal cancer (is_implicated_in)	KRAS AMER1 FAT1 BRCA1	5.36e-03	121	170	4	DOID:9256 (is_implicated_in)
Disease	Colorectal Neoplasms	KRAS LAMA1 RET TFRC FAT1 ALDH2	5.53e-03	277	170	6	C0009404

Protein segments in the cluster

Peptide	Gene	Start	Entry
STKDGLSPQELEKEY	TDRD5	21	Q8NAT2
KLGRDPTNDLTFYVS	ATAD5	1736	Q96QE3
LTYDNPDILKRVSGS	EGFLAM	846	Q63HQ2
GLDLNDTYSGKREPF	AREG	26	P15514
DGTKARLYSLQSDPA	BSDC1	116	Q9NW68
SDGDYKSPSLVSLRV	ALX3	316	O95076
DSPALLYQFRLGDEK	ACTR8	371	Q9H981
GDFLPLKAELDTTYT	CCDC171	1276	Q6TFL3
KVNLSGLPRDYLDAA	GPR12	6	P47775
RRSEELSLLKPSGDY	FERMT1	131	Q9BQL6
QKIESSPGERYLSLS	ADGRV1	526	Q8WXG9
HYGPSSLDLSKERAE	AMER1	1101	Q5JTC6
DRVTYAEKLSPLTGQ	AKAP11	1571	Q9UKA4
LLYDRDKDSGSSSPL	GLCCI1	386	Q86VQ1
PELLLGAKEYSTAVD	CDK11B	606	P21127
EKLSGLAAPDYTRLS	DOT1L	761	Q8TEK3
AGTVYPADLLSTKDE	HSD17B13	121	Q7Z5P4
GNYRDSLETLPSTKE	BPTF	1621	Q12830
ASVQEGKLDRSSPYI	CARD9	266	Q9H257
SAPEKLDRIGSYLAE	EFR3A	46	Q14156
AFRSSLYEGLEKPES	ATP2B2	1146	Q01814
SVERALAAKPGLDTY	NAGLU	51	P54802
PTLDNDDSYLGELRA	CFAP276	11	Q5T5A4
DTKQAQDLARSYGIP	KRAS	126	P01116
PLYKNGSLRNADSEI	RANBP2	761	P49792
PLYKNGSLRNADSEI	RGPD5	761	Q99666
PLYKNGSLRNADSEI	RGPD8	761	O14715
EDDNYKLSLRIEPGS	RALGPS1	276	Q5JS13
ADSSPSELKYLGLDT	RLN2	141	P04090
IPEVRLDSTYSQKAG	RGS3	856	P49796
KYPDSALGQLRIEST	KCTD19	296	Q17RG1
SDEGRKYPELVLDQS	PCDHB18P	131	Q96TA0
PSDDKALGYQLLRQT	PM20D1	401	Q6GTS8
DSDESVYKVLLLGAP	RRAD	86	P55042
SPLYKRQEESGAAAS	CHIT1	226	Q13231
SLALSELRPNDSGIY	BCAN	121	Q96GW7
RLDPATGSLYTSEKL	FAT1	1506	Q14517
DPDKYRLSQDDRDGL	MMP25	261	Q9NPA2
ESAPKASLRLGFSEY	MCM6	706	Q14566
GESASITPLEDLYKR	GDI2	41	P50395
GSGLRYQKLPSDEDE	KIDINS220	1511	Q9ULH0
NTLDRYPDTLLGSSE	KCND1	56	Q9NSA2
PLESTDGERLYKSPQ	NFIX	141	Q14938
KTLAEISDRYGAPNL	DYDC1	141	Q8WWB3
YSDSDEKPLKGSLRS	CHL1	1136	O00533
LKDPDSNPYSLLDTS	FXR2	511	P51116
EKRALTDPIQGTEYS	MALT1	556	Q9UDY8
ESPRYSLIQKGDEAT	SLC2A7	221	Q6PXP3
VDGELSRLYPSEAKS	NAB1	441	Q13506
PRKRSDSSGGYNLSD	IBTK	986	Q9P2D0
DTSAPNAKRKYLDEG	METTL14	56	Q9HCE5
RDKERDASYPLQDTT	IQSEC2	131	Q5JU85
DSPRKESLLSYLTGS	KIAA1109	2286	Q2LD37
TSPRGEEYQDKLAAE	FAM184B	541	Q9ULE4
AEDLVGKPYSQDASR	BSN	661	Q9UPA5
VYAADSNSPLLRTKD	CCDC120	491	Q96HB5
RGSVQYLPDLDDKNS	FETUB	301	Q9UGM5
DKLLDGDLTSDPSYF	CPVL	291	Q9H3G5
IRSALQDEADKPYSS	PCLO	4271	Q9Y6V0
NELTSDLDRSGIPYL	PLXNA2	1301	O75051
SPSEVTYELREGNKD	FAT2	1686	Q9NYQ8
LYQLDGLSDITEKAP	NXF5	171	Q9H1B4
AGDPSYEISKQRLSI	PCDH7	866	O60245
GQRYDSVNEKLSDSP	PCDH7	961	O60245
LDSGSLAKTYPRLDI	PDZD7	491	Q9H5P4
QVKLGSPDYVNRDSD	PFKFB4	171	Q16877
YENLSTGTRESKPDA	HACE1	416	Q8IYU2
ENDSYSRNVRGSLKP	HRNR	136	Q86YZ3
KEETPLFLAAREGSY	NOTCH3	1971	Q9UM47
NADEARSLKAYGELP	EIF1AY	96	O14602
YSEKDERESSLPNGR	RASAL2	691	Q9UJF2
QDTLERYPDTLLGSS	KCND2	56	Q9NZV8
YSLTDSRIKTGSPLD	MED12	381	Q93074
PLKNGYSEDIELASL	PLCG2	1166	P16885
LSGDLLDKDPYSFGR	TMEM63A	166	O94886
NELRPGLKYDFLSES	ADARB1	241	P78563
LKRSYTPSELEGNAV	BBS9	491	Q3SYG4
SFEALREKSNYSDIP	LRRC8B	346	Q6P9F7
DQEAKVSRSGLYRSP	CDC25C	201	P30307
DLTETSYLPRQDLEG	BRCA1	1546	P38398
AYASPAKLESIDGAR	GATD1	71	Q8NB37
ELSGKSRQYPADALE	EBLN1	31	P0CF75
DINSPESLTEAYKLR	ACOX1	476	Q15067
APDTTALDELGLSKY	CPS1	106	P31327
LADGSKVRAPYVSED	IGSF10	511	Q6WRI0
LEIYNDLPALKSSGE	IFT74	481	Q96LB3
NDLIRSKDDSPSYLP	HEATR5A	96	Q86XA9
NSGDITSLDKADYRP	DCLRE1C	566	Q96SD1
SLDLDGRFSPLYKQD	DOCK11	541	Q5JSL3
GLDSYLPELAKSARE	DOCK9	311	Q9BZ29
LEPIGAAASKEYSLE	DNAH3	991	Q8TD57
SGNGSLYTSKPLDRE	CDH10	436	Q9Y6N8
NYKDPLTGDEETLAS	FBXO7	51	Q9Y3I1
SLNSKRRELEDPGAY	GJC1	261	P36383
NSRSPEYLSLFIDDK	CUL3	381	Q13618
SGDPRYDVADAVKTL	COL6A5	1116	A8TX70
NKEAYAPQISLEGSR	GARRE1	431	O15063
LLDATYKDGRPLTDD	CYP51A1	291	Q16850
LLADERSAPEIKYNS	RAP1GDS1	541	P52306
LEKDNLELGSESRYP	GON4L	956	Q3T8J9
PLKNSSYERENLISG	CCDC66	816	A2RUB6
DAELRAIANKPSSTY	COL21A1	176	Q96P44
LRLEGLQEKDSGPYS	ESAM	111	Q96AP7
ESYDRTALKLGPESF	MAN1A2	496	O60476
ELDELASKAPVLTYG	EFHC1	61	Q5JVL4
SLAEGIARYSDPIDK	CCDC168	2481	Q8NDH2
LSLSRNPISEAEDYK	DRC3	161	Q9H069
DRLASLYKALPQSVD	FHIP2A	311	Q5W0V3
LASRNESDGLNYIPK	GTF2IRD2	811	Q86UP8
EKPDEYVSSSRSLGL	BICRA	1196	Q9NZM4
LLDTPREKNSSYSLG	S100PBP	91	Q96BU1
YAVSRGFKDLELDTP	RYR2	2901	Q92736
LYDKLGRLLTSSEEP	IPO13	446	O94829
IPAASYGRLETDTKL	PEX1	161	O43933
DRDKNLSLRYSVTGP	CDH2	186	P19022
ELLTDPRRNYTGTDK	PPP4R2	106	Q9NY27
RSKEEAPSYRTLNGA	PHF20	801	Q9BVI0
AGSSDEDKRLTRPAY	FOXL3	21	A0A1W2PRP0
DPSTLEQYDLSSLAK	IGF2R	771	P11717
KESPLLNDYRGFLAE	RTL8A	86	Q9BWD3
KESPLLSDYRGFLAE	RTL8B	86	Q17RB0
KESPLLNDYRGFLAE	RTL8C	86	A6ZKI3
FSDPYVKASLISEGR	SYT3	466	Q9BQG1
DLAPYGTLRKSQSAD	SYT12	121	Q8IV01
DPLYKNGSLRNADSE	RGPD4	761	Q7Z3J3
LADPGTSEQTDLRLY	TEX55	281	Q96M34
TSEQLKDVAYGTRPL	RPGRIP1	586	Q96KN7
SDLYRKVQPSELVGS	SOS2	791	Q07890
TPLGRLDKYAASENI	PPP4R1	46	Q8TF05
LELIDRYEPSDSGKL	PLCD4	246	Q9BRC7
NDKSRDYTRPDLPSG	PTBP2	266	Q9UKA9
GLTLDPEADSEYLSR	SVIL	121	O95425
KGGDDLDPNYVLSSR	CKM	116	P06732
EKGPEVLQDSLDRSY	NBPF20	1231	P0DPF2
KGPEVLQDSLDRSYS	NBPF20	1476	P0DPF2
KGPEVLQDSLDRSYS	NBPF20	2696	P0DPF2
RQSEAADSNPSELKY	RLN1	136	P04808
ADSNPSELKYLGLDT	RLN1	141	P04808
YTTGRKPTVLEDNLS	TAF1B	126	Q53T94
GASSDLNRLDKDPIY	LAMA1	2421	P25391
SADPDNLKYSSSRDR	SMG1	36	Q96Q15
KLLSAERAVTGYTDP	EPPK1	1641	P58107
KLLSAERAVTGYTDP	EPPK1	3366	P58107
TKLGNPTRSEDLLDY	RPN1	186	P04843
SEGREPKLNDNVSAY	MAPKAP1	216	Q9BPZ7
KLEDLSYLDGQRNAP	TANC1	321	Q9C0D5
SYLLDSENTSGALPR	NKX3-1	101	Q99801
TDLAKRFDVSGYPTL	PDIA4	241	P13667
TSYRLAKVEGEESPA	PPM1B	416	O75688
DDKDLRVYGPAESQS	KIF25	26	Q9UIL4
SYVPREAGSQKDENL	TFRC	151	P02786
EELLLGRTSPSKNYN	BTG1	151	P62324
YLKPRGSFETTADDI	MC2R	91	Q01718
RTYLAALETLDNGKP	ALDH2	116	P05091
PVNDLRGSDSIAYDK	ADD1	126	P35611
GDSLTVPTKLSQYER	C12orf50	161	Q8NA57
RKEYPNLSTSLDDAF	TTPAL	66	Q9BTX7
APEKGSLRQTYELND	PLPPR4	651	Q7Z2D5
EPFGEISSRYKADLS	RNF213	5096	Q63HN8
DYLPTENGDFLSSKR	UHRF1BP1L	896	A0JNW5
DSPDYCLENKTLGLL	WNT8B	251	Q93098
NDSYIKERSDIPSGT	USP16	421	Q9Y5T5
TSAYPKDGEVERLAS	ZFHX2	1616	Q9C0A1
QDLDSLDTEKSPLYG	TRPM5	681	Q9NZQ8
LDTEKSPLYGLQSRV	TRPM5	686	Q9NZQ8
DPKAVLRYGLDSDLS	SERPINF1	246	P36955
LSYKLELGSDQEIPS	STON1	651	Q9Y6Q2
TLLDLGASPDYKDSR	SHANK3	201	Q9BYB0
SDYGRLASEAKPAAV	TLN1	1891	Q9Y490
DDIEYLLSGLKSTQP	WAPL	656	Q7Z5K2
DGLSKIRLNYSDESP	SENP6	906	Q9GZR1
SPAKGLSVRLEFDYS	TACC2	2256	O95359
GYLRPEKNFDSLESL	RFK	101	Q969G6
QPRSLTYKESGVDIA	GART	431	P22102
KRRDYLDLAASTPSD	RET	1011	P07949
NLRLYSGSPTRSEKE	WDR59	596	Q6PJI9
DNSELGSETRYPLLL	YY1AP1	416	Q9H869
QGDSYLRVSSDSPKD	WDR62	971	O43379
SSKRTLPADYGDSLA	UBP1	291	Q9NZI7
EDTSGLLELKAVPAY	ATP6V0A4	151	Q9HBG4
QELYKADRSPSLSVA	TASOR2	211	Q5VWN6
LLKPTDSYSSQLEDR	TMC7	66	Q7Z402
VNSPALGTRTEYKEL	ZNF34	111	Q8IZ26
ELSKEDRETLYPTFG	ATP6V0D2	231	Q8N8Y2
NADEARSLKAYGELP	EIF1AX	96	P47813
SGEKAAALVDRYSTP	MUS81	486	Q96NY9
DTRYTLPLTEGKANV	MYOF	701	Q9NZM1